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ABSTRACT

Site-directed mutagenesis was used to target residues within transmembrane
domains 1 and 2 of the human equilibrative nucleoside transporter 1 (hENTl), in order to
assess their contributions to transporter functionality. Through affinity changes in
[ H]NBMPR binding, competitive inhibition profiles with ENT1 inhibitors and [ H]2chloroadenosine uptake, these residues were found to make minor, but statistically
significant, contributions to the inhibitor and/or substrate binding site of hENTl.
An initial study was also undertaken to probe the potential oligomerization of
hE N T l. Typically considered to be a monomer to this date, under the native conditions of
Blue Native Electrophoresis, hENTl was found to possess a molecular mass of 160 kDa.
This is approximately three times the size of the known 55kDa hENTl monomer.
Targeted site-directed mutagenesis of GxxxG motifs within the transporter, known to
play a role in oligomerization, did not appear to affect the higher molecular mass hENTl
complex observed.

Keywords: equilibrative nucleoside transporters, site-directed mutagenesis,
transmembrane domains 1 and 2, oligomerization, blue native electrophoresis, GxxxG
motif
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CHAPTER 1. Introduction

1.1 Nucleosides
Nucleosides are purine and pyrimidine nitrogenous bases attached to a ribose or
2-deoxyribose ring by a p- glycosidic linkage. They are the building blocks of
nucleotides, such as ATP, which are essential for energy metabolism and cell growth.
Nucleoside salvage pathways are recycling processes that are crucial in cells incapable of
de novo nucleotide synthesis (99). Nucleosides also play important roles in cell signaling,
for example, cAMP and adenosine. Extracellular adenosine acts as a ligand for purinergic
(PI) cell surface adenosine receptors to affect downstream cell signaling events (57). In
this way, adenosine regulates coronary blood flow, has cardiac effects during ischemia
independent of vasodilation, inhibits fat lipolysis, and also acts as a neuromodulator, an
anti-inflammatory agent and an anti-nociceptive agent (21, 16, 10, 73). Nucleoside
analogs are also well utilized as antiviral and chemotherapeutic agents. The flux of
nucleosides in and out of the cell is modulated to facilitate growth and to regulate
concentrations o f physiologically relevant chemicals and signaling molecules. However,
due to their hydrophilic nature, nucleosides and their analogs require the help of
specialized transporters to cross the hydrophobic cell membrane (99).

1.2 Nucleoside Transporters
In mammalian cells, nucleoside transport is mediated by two major systems, both
belonging to the Solute Carrier gene family. The class of nucleoside transporters
belonging to the SLC29 family is known as the Equilibrative Nucleoside Transporter
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(ENT) family. ENTs are typified by passive, low affinity bi-directional facilitated
transport (99). ENT orthologues can be found in many different eukaryotic species and
interestingly enough, over the course of evolutionary time the protein has undergone very
little variation (1). This high level of conservation emphasizes the physiological
importance o f ENTs. Specialized tissues like the liver, kidney and small intestine that
partake in absorptive and secretory processes additionally possess concentrative Na+nucleoside co-transport. The three members belonging to the SLC28 family are classified
as Concentrative Nucleoside Transporters (CNT) 1-3. Transport of this nature is
characterized by unidirectional, active movement o f nucleosides into the cell based on the
existing Na+ gradient (99).

1.3 Equilibrative Nucleoside Transporters
The four currently known members of the ENT family are designated ENT 1-4, of
which ENT1 and ENT2 are the most characterized. Traditionally, equilibrative
transporters were classified either as equilibrative sensitive (es) or insensitive (ei), based
on their sensitivity to inhibition by nitrobenzylthioinosine (nitrobenzylmercaptopurine
riboside; NBMPR) (99). The es transporter, now more commonly referred to as ENT1,
was originally purified from human erythrocytes and first cloned in 1996 from human
placental cDNA (22). Human ENT1 (hENTl) is 456 amino acids long and shares 78%
and 79% sequence homology with rat and mouse ENT1, respectively (97, 28). hENTl
expression has been noted to varying degrees at the mRNA and protein level in many
tissues, including erythrocytes, vascular endothelium, brain, heart, placenta and liver
(59). In terms o f cellular localization, hENTl has been found not only at the plasma

3
membrane, but also in the Endoplasmic Reticulum (ER), nuclear envelope and
mitochondria (48, 44). This intracellular es transport most likely mediates nucleoside
transport between internal cell compartments and could potentially consist o f an
intracellular reserve pool that may be recruited to the membrane when necessary (48).
The traditional ei component of equilibrative transport, ENT2, was cloned by
virtue o f its 46% sequence homology to hENTl (23, 9). ENT2 mRNA is expressed in a
number of tissues, but is particularly abundant in skeletal muscle (23). ENT3 and ENT4
are less well characterized. hENT3 contains two dileucine endosomal/lysosomal targeting
sequences and is optimally functional at pH 5.5, pointing to its physiological relevance in
acidic, lysosomal compartments (4, 72). The more recently characterized ENT4 was
initially described as a monoamine/organic transporter (PMAT), as it strongly transports
organic cations like serotonin and MPP+ (13, 14). It has since been found to possess some
capacity as a pH dependent transporter of adenosine (5).

1.4 Molecular Properties of ENTs

1.4.1 Purification of ENT1
The es transport system was initially purified using NBMPR as a specific high
affinity probe by measuring [3H]NBMPR binding in proteins that were extracted from
human erythrocyte membranes and purified by ion-exchange chromatography. This
preparation consisted mainly o f band 4.5 polypeptides, which consist of nucleoside
transporters and glucose transporters (34). The presence o f purified es transporters was
verified by measurable uridine transport that was inhibited by ENT1 inhibitors when this
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preparation was reconstituted in liposomes (84). Photoaffinity labeling is a technique that
covalently links radioactive NBMPR to the transporter upon exposure to UV light. Using
this technique, the existence o f es transport in band 4.5 polypeptides was further
confirmed (98). Radioactivity was measured in band 4.5 polypeptides and no
radiolabeling was present in cells lacking nucleoside transporters (95). Because the band
4.5 preparation contains glucose transporters in addition to nucleoside transporters,
further purification was achieved using pig erythrocytes which highly express nucleoside
transporters and lack functional glucose transporters (43). The es transporter has also
been separated from glucose transporters and purified in human erythrocytes (41). This
has ultimately allowed the successful cloning of hENTl from human placental cDNA
( 22).

1.4.2 Development of Antibodies to ENT1
The successful purification o f nucleoside transporters has since allowed for the
development o f ENT1-specific antibodies. SDS-PAGE with purified es transporters of
different species migrate at different sizes but they are clearly related proteins based on
the cross reactivity o f developed antibodies amongst species (42). The broadness of the
band is a result o f the glycosylation state of the transporter and can be reduced to a
sharper band with deglycosylation treatment. Human erythrocytes migrate at a broad Mr
55000 band. When deglycosylated with endoglycosidase F, es transporters of human
erythrocytes migrate at a sharp band of 45000 (40). The es transporters in pig
erythrocytes migrate as a broad band and a deglycosylated sharp band at Mr= 64000 and
57000, respectively (40). The rat es transporters migrate at approximately 64000 and
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endoglycosidase F treatment produces a sharp band of Mr= 45000 (96). According to the
Expert Protein Analysis Server (ExPASy) of the Swiss Institute o f Bioinformatics (SIB),
the predicted molecular weight of the hENTl protein based on amino acid sequence is
50219.4. The molecular weight o f the deglycosylated transporter is slightly lower than
the predicted protein size.

1.4.3 ENT Substrate and Inhibitor Selectivity
ENT1 transporters in mammalian cells exhibit a wide range o f substrate transport
affinities with Km values from 20pM to 2-4mM (62). hENTl has a broad substrate
selectivity, transporting both pyrimidine and purine nucleosides as well as anticancer
agents, but not nucleobases (99). hENTl is unable to transport antiviral agents that are 3’deoxynucleoside analogs, pointing to the importance of the 3’-hydroxyl on the sugar ring
as a key functional group for substrate recognition and binding (87). hENT2 has a lower
affinity for nucleosides than hENTl but has the capacity to transport a wide range of
purine and pyrimidine nucleobases, in addition to nucleosides. hENTl and hENT2 also
differ in terms o f their affinities for ENT inhibitors. Inhibition by NBMPR of ENT 1 is
effective in the low nanomolar range with Ki values observed anywhere from 0.1 - 10
nM. Conversely, ENT2 is only sensitive to inhibition by higher micromolar
concentrations o f NBMPR (21). This differential sensitivity is the basis of the traditional
classification o f es and ei nucleoside transporters. A similar trend is true for the
cardiovascular inhibitors dipyridamole and dilazep, which inhibit hENTl 100 - 1000 fold
more effectively than hENT2 (21).

Figure 1.1 ENT1 inhibitors and substrates
Chemical structures o f the ENT1 inhibitors (A) Draflazine, [2-(aminocarbonyl)-4-amino2,6-dichlorophenyl)-4-[5,5-bis(4- fluorophenyl) pentyl]-1-piperazine acetamide 2HC1]
(B) Dilazep, (N,N'-bis[3-(3,4,5-trimeth-oxybenzo-yloxy)propyl]-homo-piperazine) (C)
Dipyridamole,

[2,6,-bis (diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d]pyrimidine]

(D) NBMPR, nitrobenzylemercaptopurine ribonucleoside and the ENT1 substrate (E) 2chloroadenosine.
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A. Draflazine
F

B. Dilazep

C. Dipyridamole

OH

OH

OH OH
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Although all ENT1 transporters have an equally broad permeant selectivity, it is
important to note that affinity ranges vary greatly across species and within different cell
lines. As a result of the difficulty in compensating for different membrane environments
and co-expression of multiple transporters, the functional characterization of recombinant
nucleoside transporters is typically assessed in one o f three different expression systems;
Xenopus laevis oocytes, Saccharomyces cerevisiae or cultured mammalian cells. The
range of Km values for hENTl nucleoside substrates in cultured mammalian cells is
40pM to 580pM (100). Substrate and inhibitor affinities for the porcine kidney (PK-15)
epithelial nucleoside transport- deficient (NTD) mammalian cell line stably transfected
with hENTl that was used for this study are presented in Table 1 (92).

1.4.4 Proposed Mechanism of Substrate Transport by ENT1
Nucleoside transporters are proposed to function by the ‘alternating access
mechanism’ whereby permeants bind to an extracellular site on the transporter, inducing
a conformational change (35). This change reorients the transporter, allowing the
permeant to be released intracellularly. hENTl is believed to have an outward and an
inward facing conformation, and is able to alternate between both conformations
regardless o f whether permeant is bound or not. However, the rate o f conformational
change does differ depending on the particular permeant bound. In human erythrocytes,
the rate of conformational changes when different permeants are bound has been shown
to increase with pyrimidine nucleosides, decrease with 2-chloroadenosine, and stay the
same with adenosine (21). NBMPR bound extracellularly to ENT1 appears to lock the
transporter in the outward facing conformation (35).

9

Km values o f nucleoside substrate uptake by PK15 hENTl cells
Adenosine

50 ± 10 pM

Guanosine
Inosine
Uridine
Thymidine
Cytidine

140 ± 20 pM
200 ± 50 pM
480 ± 260 pM
240 ± 60 pM
680 ± 130 pM

Kd values for inhibitor binding to PK15 hENTl
NBMPR (Whole cells)
NBMPR (Membranes)

0.377 ± 0.098 nM
0.17 ± 0.03 nM

Table 1.1 Characterization of hENTl stably transfected in pig kidney epithelial
nucleoside transport deficient (PK15NTD) cells
The affinity (Km) o f PK15 hENTl for the uptake of nucleoside substrates is presented in
pM. The affinity (Kd) in nM of concentration-dependent [3H]NBMPR binding to PK15
hENTl whole cells and crude membranes is also given. These values are those reported
by Ward et al. 2000 (92), who initially generated and characterized the PK15 hENTl cell
line.
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More recently, the possibility o f an allosteric model has been proposed (25). The
first high affinity binding site is where NBMPR and substrates bind the transporter.
Competitive inhibition profiles suggest that the binding site o f [3H]NBMPR and
substrates is the same, or at the very least, overlapping. A study of chemically altered
NBMPR analogs with substitutions at the 2’- and 3’- positions resulted in reduced
NBMPR binding and transport inhibition of hEN Tl, meaning that these groups are
important for the high affinity NBMPR binding site (102). This mimics the fact that the
2’- and 3’-OH groups are well known to be crucial for hENTl substrate recognition (99).
The second site is proposed to have a much broader specificity, binding
nucleosides, nucleobases and inhibitors with a much lower affinity than the
substrate/NBMPR-binding site. In this way, the second site modulates the high affinity
substrate/NBMPR-binding site in an allosteric fashion (21). There is quite a bit of
evidence for the notion of an allosteric binding site. Inhibitors like dipyridamole and
lidoflazine analogues have been shown to inhibit [3H]NBMPR binding with pseudo-Hill
coefficients not equal to unity, suggesting cooperativity (29, 30, 36, 26). Nucleoside
substrates and inhibitors have also been shown to affect the rate of dissociation of
[3H]NBMPR binding. Nucleosides accelerate the rate of dissociation of [3H]NBMPR
(32). Conversely, inhibitors like dipyridamole, dilazep and lidoflazine analogs decrease
or do not change the rate of [3H]NBMPR dissociation (32, 25). These findings suggest
the presence of a second, lower affinity site that modulates the first, high affinity site. It
has been suggested that these results are due to nonspecific membrane binding due to the
high inhibitor concentrations required for rate dissociation studies, and not a second site.
However, studies using Ehrlich ascites membranes that were solubilized with
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octylglucoside, to better mimic the native lipid environment, confirmed that differences
in dissociation rates observed were not a nonspecific effect (25).

1.5 Clinical Relevance of hENTl
The propensity o f ENTs for transport of chemotherapeutic and antiviral agents
make them great candidates for clinical drug development. Over the years a number of
nucleoside analogs have been developed for clinical use, and are currently approved for
treatment of various cancers and viral diseases (100). Like natural nucleoside permeants,
the selectivity o f developed nucleoside analog drugs varies amongst nucleoside
transporters. hENTl has been shown to transport anticancer agents such as fludarabine
(9-p-D-arabinosyl-2-fluoroadenine),

cladribine

(2-chloro-2’-deoxyadenosine),

clofarabine [2-chloro-9-(2’-deoxy-2’-fluoro-P-D-arabinofuranosyl) adenine], gemcitabine
(2’,2’-diflurodeoxycytidine)

and

cytarabine

(1-P-D-arabinofuranosylcytosine)

(99).

hENT2 more efficiently transports antiviral agents like zalcitabine (2’,3’-dideoxycytidine
or

ddC),

didanosine

(2’,3’-dideoxyinosine

or

ddl)

and

zidovudine

(3’-azido-

3’deoxythymidine or AZT). Like hENTl, hENT2 is additionally able to transport
cladribine, gemcitabine and clofarabine (99).
The basic mechanism of nucleoside analog drug cytotoxicity is as follows: Once
drugs

are

transported

into

the

cell

by

nucleoside

transporters

they

are

monophosphorylated by nucleoside kinases. The monophosphorylated drug derivatives
are further phosphorylated by 5’ nucleoside monophosphate and 5’ nucleoside
diphosphate kinases. These triphosophorylated nucleoside analogs are then able to
integrate into DNA and RNA, causing chain termination and ultimately, cell death (18).
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Nucleoside transporters can be used to advance cancer treatments in ways other than the
development o f nucleoside analog drugs. Malignant tumour cells tend to have increased
hENTl expression, consistent with the association of hENTl with generalized cell
growth and proliferation (100). The development of fluorescent imaging NBMPR analogs
such as SAENTA [5’-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5’-thioadenosine] fluorescin
(93) can help to quantify hENTl expression in cancer cells prior to cytarabine treatment,
in order to pre-determine drug efficacy in individual patients (100). This can also be
translated to chemoresistance. Nucleoside transporter deficient cell lines have been
shown to be extremely resistant to anticancer nucleoside drugs. A study with acute
leukemia patients used imaging agents prior to treatment to correlate decreased hENTl
expression to shorter disease-free survival (18).

1.5.1 ENT1 Inhibitors as Cardiovascular Drugs
In addition to being an important factor in the effectiveness o f chemotherapeutic
nucleoside analogue drugs, ENTs are also clinically exploited for their physiological
influence on adenosine and its protective roles within the body (21). Inhibitors of ENTs
block nucleoside uptake, effectively increasing the cardioprotective effects of adenosine
by maintaining extracellular concentrations of the nucleoside. Extracellular adenosine
activates adenosine receptors, resulting in vasodilation that increases blood flow to
cardiac and cerebral tissues under ischemic stress or high metabolic activity (10, 21).
Dipyridamole is a pyrimidopyrimidine derivative that is clinically used as a coronary
vasodilator and a platelet aggregation inhibitor. Due to its poor oral bioavailability, high
doses of dipyridamole need to be taken. It is also not a pharmacologically specific
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compound. Dilazep is a symmetrical alkyl and cycloalkyldiamine aromatic ester that is
also used as a coronary vasodilator and platelet aggregator. Lidoflazine and its analogues,
including draflazine, are Ca2+ channel blockers, in addition to ENT1 inhibitors, that
appear to have better oral bioavailability (56). It is clear that there are a number of
avenues by which a basic knowledge of nucleoside transporters and their permeants can
be clinically beneficial. In order to better aid future drug design, it is useful to have
knowledge o f the ENT substrate and inhibitor binding domains.

1.6 Structural Features of hENTl
Due to the hydrophobic nature of this membrane transporter, 3D X-ray
crystallographic structures of ENT are currently unavailable. This lack of knowledge of
the structural details of hENTl hinders the progress of chemotherapeutic and adenosine
uptake inhibitor drug development. Hydropathy profiles, glycosylation scanning
mutagenesis and studies with antibody (Ab) probes have proposed an 11 transmembrane
(TM) domain model (Figure 1.1) with a cytoplasmic N-terminal and an extracellular Cterminal. There is a large extracellular loop between TM 1 and 2 that is glycosylated at
residue Asparagine 48 (80). Glycosylation is not necessary for hENTl transport, but it
may affect binding affinities of the inhibitors NBMPR and dipyridamole (86).

1.6.1 Site-Directed Mutagenesis Studies
To date, structure-function studies with point mutants have been helpful in
attempting to map the hENTl permeant binding site. An initial study that generated
chimeric human and rat ENT1 constructs took advantage o f the differential inhibitor

Figure 1.2 Schematic representation of the predicted topology of hENTl
The transporter is proposed to have 11 transmembrane domains, an intracellular Nterminus (NH 3+) and an extracellular C-terminus (CO 2’). The large extracellular loop
between TM 1 and 2 contains an N-linked glycosylation site. The shaded residues are
those in the first two TM segments and surrounding the GxxxG motifs o f TM 4 and 11
that have been previously studied. Residues that have been targeted in this study are
highlighted with boxes and in order, from left to right, are G22, N81, C87, T96, G163
and G445.
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sensitivity of the human and rat ENT1 species to determine which gross structural
portions of the transporter were responsible for interactions (81). While both human and
rat ENT1 are inhibited by low concentrations o f NBMPR, only the human variant of
ENT1 is sensitive to inhibition by the coronary vasodilators, dipyridamole and dilazep at
lower concentrations. Using these approaches, the TM 3-6 region of hENTl was found to
be responsible for conferring dipyridamole and dilazep sensitivity. The TM 1-2 region
was additionally suggested to make minor contributions to dipyridamole sensitivity (81).
Subsequent studies have since implicated a number of residues that make contributions to
substrate and inhibitor binding (99). Random mutagenesis and subsequent phenotypic
complementation screening in yeast has revealed multiple mutants with altered resistance
to hENTl inhibitors. As the findings of the chimeric study alluded to, a few of these
residues are within TM 1 and 2.

1.6.2 Transmembrane Domains 1 and 2 of hENTl
The methionine 33 residue of hENTl is an important determinant of sensitivity to
dipyridamole and dilazep, but not NBMPR (90). While dipyridamole and dilazep inhibit
hENTl at nanomolar concentrations, hENT2 is several orders o f magnitude less sensitive.
The hE N T l-M331 mutant was approximately 10-fold more resistant to inhibition by
dipyridamole and dilazep than wild-type hENTl. This is of interest since the
corresponding residue in hENT2 is, in fact, isoleucine. The complementary mutation of
isoleucine 33 to methionine in hENT2 consequently resulted in a reversal of effect i.e. an
increase in vasodilator inhibitor sensitivity (90). Mutation of the residue leucine 92 to
both proline and glutamine resulted in resistance to NBMPR and dilazep, but not
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dipyridamole (11). Integration of this finding with the M33 results clearly suggests that
inhibitors have overlapping but distinct binding sites. This is a reasonable idea given the
fact that in terms of chemical composition, NBMPR is an analogue of the natural
nucleoside inosine while the vasodilator inhibitors are structurally unrelated molecules.
The L92Q mutant also displayed purine selective transport for the nucleosides inosine
and guanosine, but not for adenosine or pyrimidines (11). Mutations of the residue
tryptophan 29 to glycine, cysteine, alanine, tyrosine, valine and threonine affected
inhibitor interactions with NBMPR, soluflazine, dipyridamole and most significantly,
dilazep. W29T was additionally incapable of pyrimidine transport and displayed less
efficient purine transport. A tryptophan residue appears to be the best choice at position
29 of hEN Tl, as none o f the mutants had transport efficieny comparable to the wild-type
transporter (58).
Another study found that double mutation of the residues methionine 89, of TM 2,
and serine 160, of TM 4, decreased the sensitivity to inhibition by NBMPR in a
synergistic manner. On their own, the M89C mutation was mainly responsible for a
decrease in affinity for adenosine transport, while the S160C mutant displayed an
increased resistance to dipyridamole inhibition (12). While single point mutations exert
their own separate effects, this study clearly showed that residues in separate TM
domains work together to interact with inhibitors and substrates in a concomitant manner.
It is important not to restrict residues interactions to those nearby one another on a
hydropathy plot or within a TM domain, but to try to visualize interactions in terms of the
three-dimensional conformational structure of the transporter.
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The studies mentioned focus on TM 1 and 2, but numerous residues within other
transmembrane regions are of significant importance to transporter function as well (76,
77, 88, 89). The scattered pattern o f implicated residues throughout the transporter
suggests that hENTl permeant binding and translocation involves a number of
overlapping high affinity binding sites and complex interactions between multiple TM
domains. More recently, based on a common evolutionary origin between ENT and MFS
(Major Facilitator Superfamily) transporters, Baldwin et al. have generated a model for
PfENTl, a Plasmodium falciparum ENT, using the MFS (Major Facilitator Superfamily)
transporter GlpT (glycerol 3-phosphate/phosphate exchange transporter) as a template.
This model suggests that TMs 1, 2, 4, 5, 8 and 11 may surround the solvent accessible
permeant binding site of the transporter (99). A more recently proposed ab initio model
of the L dN T l.l transporter further confirmed this model. This model suggests that TM
domains 1, 2, 4, 5, 7, 8, 10 and 11 surround an inner hydrophilic cavity, and that more
specifically TM domains 1, 10 and 11 line the permeation pathway (85). However,
characterization of m E N T lA ll, a splice variant of the full-length mENTl protein that
results in a C-terminal truncated version (missing the last three TM domains), showed
that m E N T lA ll did not differ from mENTl in terms of transport capacity or inhibitor
binding affinity. This suggests that TM domains 9, 10 and 11 are not necessary for the
functional capacity of the transporter. This contradicts the threaded and ab initio
nucleoside transporter models, and caution should be taken in interpreting findings across
ENT species.
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1.7 Oligomerization
Over the recent years, an increasing amount o f published data has emerged
implicating the dimerization and higher-order oligomerization o f a number of membrane
transporters and receptors, including tyrosine-kinase receptors, G-coupled-proteinreceptors (GPCRs), monoamine and glucose transporters, among others (82). GPCRs
were initially considered to be monomeric proteins, but the existence of higher-order
oligomerization is now generally well accepted. Initial studies that identified p-adrenergic
receptors using radioligand binding observed negative cooperativity amongst binding
sites, indicative o f interaction between receptor monomers (47). A number of studies
throughout the 1970s and 1980s using photoaffinity labeling, radiation inactivation,
cross-linking and gel filtration further supported the notion of GPCR oligomerzation (6).
In terms o f nucleoside transporters, there is steadily mounting evidence to suggest the
existence o f oligomerization in the form of radiation inactivation studies (31),
photoaffinity labeling (69) and negative cooperativity of inhibitor binding (26, 36). There
is, however, not yet a complete picture of the conformational structure of the individual
transporter, nor is there knowledge of transporter interactions with other nucleoside
transporters in the surrounding environment.

1.7.1 The Role of GxxxG Motifs in Oligomerization
The GxxxG m otif is a well-established dimerization m otif first notably
documented in Glycophorin A (GpA). GpA from human erythrocytes was first shown to
dimerize almost 30 years ago through specific interactions of its single a transmembrane
helix (17). More recently, the GxxxG m otif was identified in a statistical analysis of
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transmembrane helical sequences in the SwissProt database (70). The m otif was found to
occur at a frequency o f approximately 32% higher than randomly expected. A
randomized sequence cDNA library search for transmembrane helix packing motifs
consistent with high-affinity oligomerization yielded the presence of the GxxxG motif in
over 80% of the sequence isolates (70). The m otif works by aligning the three-residue
separated glycine residues along one face of the a-helix. This provides a relatively flat
surface for optimal binding to another transmembrane a-helix. The x ’s in the GxxxG
m otif can be any amino acids, but most frequently tend to be large, hydrophobic residues
like valine, leucine and isoleucine. This combination of bulky p-branched residues with
small, flexible glycine residues increase the strength of van der Waals contacts necessary
for stable dimerization (70).
At the point o f identification in the SwissProt database, the GxxxG motif was
already documented in GpA, but afterwards the m otif and other GxxxG-like motifs were
found in a number o f other receptors and proteins. Examples include human carbonic
anydrase, the epidermal growth factor receptor (ErbB) family, integrins, GPCRs, the
E.coli lactose permease and yeast ATP synthase, amongst others (50, 74, 75, 71).
Although there are currently no studies available on the subject, this thesis will attempt to
discuss literature suggestive of nucleoside transporter oligomerization and provide
introductory evidence that hENTl forms a dimer or higher order oligomer.
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CHAPTER 2. Rationale, Hypothesis and Research Objectives

2.1 Research Hypothesis and Rationale: TM 1 and 2
The noted significant contributions of TM 1 and 2 to the functional capacity of
hENTl suggests that this is a reasonable region of interest to focus on. Helical wheel
projections o f TM1 and 2 (Figure 2.1) indicate that the previously identified residues
methionine 33 and tryptophan 29 of TM1, and methionine 89 and leucine 92 of TM2, are
clustered together. There is no clearly exofacial side to these two transmembrane regions
that is comprised purely o f charged, hydrophilic residues. Based on polarity, potential
steric interactions and proximity with respect to the previously identified key residues,
the residues glycine 22 o f TM1 as well as asparagine 81, cysteine 87 and threonine 96 of
TM2 were targeted to assess their importance in the binding and functionality of hENTl
mediated transport.
Glycine residues are essential for providing flexibility within transmembrane
helices. Mutations of glycine 179 to valine, leucine or cysteine residues abolished hENTl
transporter activity without disrupting targeting to the membrane. Mutation of glycine
179 to alanine decreased uridine transport, and decreased sensitivity to inhibitors
NBMPR and dipyridamole (76). Glycine 154 of hENTl has also been identified as
having decreased sensitivity to NBMPR, dipyridamole and dilazep and reduced transport
affinity when mutated (77). A PWN (Proline-Tryptophan-Asparagine) m otif in the Nterminus o f hENTl was found to be crucial for targeting to the membrane, with mutations
of proline 28 disrupting plasma membrane localization (56). The tryptophan of this motif,
W29, as already mentioned, was found in another study to affect hENTl nucleoside
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transport and inhibitor sensitivity (58). In helical wheel projections of TM2 (Figure
2.1 A), glycine 22 is positioned beside tryptophan 29, as well as alongside another
tryptophan and phenylalanine. With a side chain of hydrogen, it is possible that glycine
22 is a positional necessity between these bulky aromatic side chains for flexibility.
Based on previous reports o f glycine residues affecting sensitivity to inhibitors and
substrate kinetics, as well as the possibility of positional flexibility for stacking
mechanisms of aromatic rings, we believe that mutation of glycine 22 to an alanine
residue will affect hENTl functionality.
Asparagine 81 was chosen as a residue of interest because it forms an asparagine
pair with residue 82. Polar residues like asparagine and to a slightly lesser extent,
threonine, have been shown to drive helix-helix association by forming inter-helical
hydrogen bonds in both micelles and biological membranes (7, 101). Experiments with
model peptides in micelles indicate that asparagine residues have a large driving force
towards association based on position within the hydrophobic transmembrane region, i.e.
the more buried the Asn, the stronger the driving force for association (45). Asparagine
residues have a strong tendency to be buried in the membrane protein interior compared
to other residues like valine or leucine, which tend to occupy surface accessible areas
(45). This allowed us to hypothesize that asparagine 81 and threonine 96 residues are
both potentially a driving force for helical associations, and that mutation of these
residues would affect hENTl functionality.
Sulfhydryl modifying agents have been shown to affect ligand binding of
nucleoside transporters

(61, 91). The effects of p-chloromercuriphenylsulfonate

(/?CMBS) and A-ethylmaleimide (NEM) on es transporters of mouse Ehrlich ascites cells

Figure 2.1 Helical wheel projections of hENTl (A) TM domain 1 (B) TM domain 2
The residues that have been addressed in previous studies are highlighted with arrows.
Residues that are targeted in this thesis have stars beside them. In these helical wheel
projections the squares and circles represent hydrophobic and hydrophilic residues,
respectively. The residues are numbered according to their amino acid sequence in
hENTl and are labeled by their one letter amino acid code.
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and human erythrocytes have been shown to inhibit [ H]NBMPR binding and
dissociation kinetics (91). O f the ten cysteine residues found in hENTl, only one is
located within the first two transmembrane domains. Although this cysteine is on the
opposite side of the helical wheel projection (Figure 2.IB) as the previously identified
M89 and L92 and the targeted, N81 and T96 residues of TM2, the relative infrequency of
cysteines within transmembrane segments makes this a target o f interest. When actually
present within a protein, the reactive disulfide bonds o f cysteine residues also generally
tend to be found in enzymatic sites, making cysteines residues of interest in the
functionality o f hENTl binding sites.

2.2 Research Hypothesis and Rationale: hENTl Oligomerization
The

finding

that

(3-adrenergic

receptor binding

sites

showed

negative

cooperativity was one of the first real indicators of adrenergic receptor oligomerization
(47). This is strikingly similar to the previously mentioned studies that showed
dipyridamole inhibition o f [3H]NBMPR binding in ENT1 transporters resulting in
Pseudo-Hill coefficients less than unity (26, 36). This negative cooperativity could be a
potential first sign of nucleoside transporter oligomerization. Furthermore, irradiation
inactivation of NBMPR binding and uridine flux estimated that nucleoside transporters in
human erythrocytes had an estimated in situ size of 120,000 (31). This is approximately
double the size of the monomer, and is another line of evidence suggesting that the ENT1
transporter may exist as a dimer.
Previous studies in our lab of mouse ENT1 photoaffinity labeled with
[3H]NBMPR (Figure 2.2) showed an approximate 50kDa band corresponding to the
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ENT1 monomer size. Interestingly enough, a higher molecular weight band that is
approximately twice the size, at lOOkDa, was also observed (69). Western blots of wildtype hENTl protein separated by SDS-PAGE that were probed with primary Anti-FLAG
Ab have also shown a higher molecular weight band in addition to the 55kDA FLAGtagged hENTl monomer band (Hammond et al, unpublished). Other sources in the
literature have noted higher molecular weight bands on immunoblots stained for rENTl
(Figure 2.3), namely in crude membrane preparations o f rat liver tissue (42), in rat
sinoatrial node tissue (53) as well as adult rat dorsal root ganglion and dorsal horn
homogenates (19). This higher molecular weight band has also been seen in immunoblots
o f recombinant hENTl stably transfected in Saccharomyces cerevisiae (86). The authors
of these papers all suggested nucleoside transporter oligomerization as a possible
explanation for the higher molecular weight bands observed.
Based on these observations, we hypothesized that hENTl exists as a potential
dimer or higher-order oligomer in its native state. To test this hypothesis, we have chosen
to use the Blue Native Electrophoresis (BNE) technique as a means of predicting protein
size under native, non-reducing conditions (94). hENTl also contains two GxxxG motifs
in TMs 4 and 11, known for their role in the helical associations of oligomerization. The
GxxxG m otif of TM 11 in hENTl is conserved across a number of species and ENT
subtypes (Figure 2.4B). The positional necessity for the first residue of the GxxxG motif
to be small (i.e. glycine, alanine or serine) is conserved across ENT species for the region
corresponding to the TM 4 segment o f hENTl, with the exception o f PfENTl (Figure
2.4A). In addition to the potential oligomerization o f hENTl, we also hypothesized that
these GxxxG motifs in TM4 and TM 11 play a role in that higher-order interaction of

Figure 2.2 Photoaffinity labeling of PK15-mENTl with [3H]NBMPR
Protein membranes of mENTl stably transfected in PK15 cells were incubated with
[3H]NBMPR, exposed to UV light and separated by SDS-PAGE. The amount o f
radioactivity in 2mm gel slices was plotted against migration distance on the gel. The
protein ladder (kDa) is at the top of the figure. The ENT1 monomer is visible as a 48 kDa
peak, which is the expected size o f mENTl. A higher molecular weight peak at
approximately 100 kDa is additionally observed, hypothesized to be a potential dimeric
form of ENT 1.

Figure taken from Robillard et al. 2008 (69).
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Figure 2.3 ENT1-stained immunoblots of various tissue preparations separated by
SDS-PAGE
(A) rat dorsal horn homogenate stained with anti-hENTl Ab (lane 1) and anti-rENTl Ab
(lane 2) (B) adult rat dorsal root ganglion homogenate stained with anti-rENTl Ab (C)
rat sinoatrial node (LV- left ventricle, RA- right atrium, IR- intercaval region) stained
with anti-rENTl Ab (D) rat liver crude membranes stained with control rabbit IgG (lane
A) or affinity-purified anti-nucleoside transporter Ab (lane B) (E) hENTl stably
transfected in S. cerevisiae yeast (lane 2) and empty vector pYES2 (lane 1) stained with
anti-hENTl Ab. Protein markers are placed at the right or left side o f each respective
immunoblot. The stronger lower molecular weight bands ranging from 47 to 60 kDa
represent the ENT1 monomer. The precise molecular weight is dependent on the species
of ENT1. The higher molecular weight bands at approximately 100 kDa are potential
oligomeric forms of ENT 1.

Figure adapted from various papers: Govemo et al. 2005 (19), Musa et al. 2002 (53),
Kwong et al. 1992 (42) and Vickers et al. 1999 (87).
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nucleoside transporters. Mutation of the second ‘G’ of the m otif in both regions i.e. the
residues glycine 163 and glycine 445, to non-polar leucine residues will serve to
characterize any involvement of the GxxxG m otif in an introductory manner.
In making an assessment of the contributions of the GxxxG motifs to
oligomerization, there is a great deal of choice in determining the appropriate amino acid
substitution to make. An in vitro mutagenesis study of GpA was undertaken to mutate
every residue of the 23-long residue TM domain to different residues amino acids
classified as: hydrophobic, slightly polar, strongly polar or mutation to a proline (46).
Separation of wild-type GpA with SDS-PAGE is consistently seen as a double band, so
mutants

were

screened

for

dimerization by

SDS-PAGE

and

immunoblotting.

Replacement of residues within the m otif all abolished dimerization to varying extents
but the most consistent destabilization was seen with the glycine residues, G79 and G83
(46). The substitution of polar residues affected dimerization but additionally affected
protein mobility and interaction with the detergent micelle. Because of it unique torsion
angles, mutations to proline distorted the helical backbone of peptides. The most suitable
candidates for substitutions within the motif are non-polar residues. Mutations to G79
generally disrupted dimerization, with the exception o f alanine, which was tolerated. All
mutations to G83 completely abolished dimerization with the most significant disruptions
resulting from valine, leucine, isoleucine, alanine and methionine substitutions (46). G83
is the second ‘G ’ in the GxxxG m otif of GpA. The residues that are targeted in this study
are also the second ‘G V in the GxxxG motifs of hEN Tl, namely, G163 (TM 4) and
G445 (TM 11).

Figure 2.4 Amino acid sequence alignment of the residues surrounding the two
GxxxG motifs found in ENT orthologues (A) GxxxG motif in TM 4 region of
hENTl. (B) GxxxG motif in TM 11 region of hENTl
The conserved glycine residues o f the m otif are highlighted. The numbers at the
beginning and the end o f the sequences show the positional placement o f the residues
within each amino acid sequence. The origin o f the species is indicated by the letters, hhuman; m- mouse; r- rat; Pf- P. falciparum; Ld- L. donovani.
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Different studies seem to have had varying success either with making small to
large (glycine to leucine), or more conservative (glycine to alanine) mutations. For
example, a study o f the single TM domain of subunit e in the F0F]-ATP yeast synthase,
which contains a GxxxG m otif that is essential for oligomerization, found that sitedirected mutagenesis o f the glycine residues to leucine sufficiently impaired F0F 1-ATP
synthase oligomerization (2). The contributions of the mutation were assessed by native
gel electrophoresis. Based on the significant and consistent loss in dimerization of glycine
to leucine GpA mutants (46), this substitution was chosen as an initial analysis of the
hENTl GxxxG motifs for this study. Glycine and leucine have sufficiently different
properties that this was chosen as an initial indicator o f the gross structural effects of
mutation on the dimer structural interface. Glycine residues mutated to alanine residues
are a more conservative approach to fine-tune the contributions o f the GxxxG motifs to
hENTl functionality that will be undertaken at a later point in time. To our knowledge,
no

previous

work

has been performed to

specifically

address

the potential

oligomerization state of hENTl.

2.3 Objectives
1. Characterize the functional importance of G22A, N81A, C87S and T96A in hENTl
inhibitor binding and substrate transport kinetics.
2. Test the molecular mass of hENTl in a native, non-reducing environment.
3. Assess the impact o f GxxxG motif mutations, G163L and G445L, on hENTl inhibitor
binding, transporter function and oligomerization state.
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CHAPTER 3. Materials and Methods

3.1 Materials
2-Chloroadenosine, dipyridamole [2,6,-bis (diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine],

NBMPR,

nitrobenzylthioguanosine

riboside

[NBTGR;

S-(4-

nitrobenzyl)-6-thioguanosine], and p3xFLAG-CMV10 vector, were purchased from
Sigma-Aldrich (Oakville, ON, Canada.). Draflazine [2-(aminocarbonyl)-4-amino-2,6dichlorophenyl)-4-[5,5-bis(4- fluorophenyl) pentyl]-1-piperazine acetamide 2HC1] was
acquired from Janssen Research Foundation (Beerse, Belgium). Dilazep (N,N'-bis[3(3,4,5-trimeth-oxybenzo-yloxy)propyl]-homo-piperazine) was provided by Asta Werke
(Frankfurt, Germany). [3H]NBMPR (5.5-20.1 Ci/mmol), [3H]2-chloroadenosine (9.1
Ci/mmol), and 3H-labeled water (1 mCi/g) were purchased from Moravek Biochemicals
(Brea, California, USA). Modified Eagle's Medium (MEM), sodium pyruvate, nonessential

amino

acids,

Geneticin®

(G418),

Lipofect AMINE™

2000,

penicillin/streptomycin, trypsin/EDTA, and culture-grade phosphate-buffered saline
(PBS) were purchased from Invitrogen (Burlington, ON, Canada). BGS was purchased
from ThermoScientific, Hyclone Laboratories (Utah, USA). T175 flasks, T75 flasks, 6,
12 and 24 well plates were purchased from BD Biosciences (Bedford, MA, USA).
Whatman

GF/B

filters

were

purchased

from

GE

Healthcare

UK

Limited

(Buckinghamshire, UK). PK15-NTD (Pig Kidney nucleoside transporter deficient) cells
and the hENTl-pcDNA3.1 construct were a generous gift from Dr. Ming Tse (Johns
Hopkins University, Baltimore, MD). Oligonucleotide primers were designed and
purchased from Sigma-Genosys (Oakville, ON, Canada). The Quikchange® II Site-
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Directed Mutagenesis kit was purchased from Stratagene (California, USA). The
QIAprep® Spin Miniprep Kit was purchased from Qiagen (Mississauga, ON, Canada).
Cloning cylinders were purchased from Bel-Art Products (Pequannock NJ, USA).
TRIZOL® Reagent, Superscript™ First Strand Synthesis System for RT PCR,
Platinum®

Pfx DNA Polymerase, the PureLink™

Quick Gel Extraction Kit,

NativePAGE™ Novex® BisTris 4-16% gradient native gels, the XCell SurelLock™ MiniCell electrophoresis system and NativeMark™ Unstained Protein Standard were
purchased from Invitrogen (California, USA). Coomassie Blue G-250, Triton-XlOO (TX100) and n-Dodecyl-P-D-maltoside (DM) were purchased from Sigma (Oakville, ON,
Canada). The primary monoclonal mouse anti-FLAG Ab and secondary goat anti-mouse
Ab were purchased from Sigma (Oakville, ON, Canada). Goat primary Ab to GAPDH
and secondary goat anti-rabbit Ab were purchased from Abeam (Cambridge, MA, USA).
Primary rabbit polyclonal SLC29A1 Ab was purchased from AbNova (Walnut, CA,
USA). Secondary donkey anti-goat Ab was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Cell lysis buffer (10X) and LumiGLO® chemiluminescent
substrate were purchased from Cell Signaling Technology (Danvers, Massachusetts,
USA). The mammalian protease inhibitor cocktail was purchased from Calbiochem
(California, USA). The Bradford colorimetric protein assay was purchased from Thermo
Fisher Scientific (Waltham, MA, USA). Precision Plus Protein™ Dual Colour Standard,
the Mini-PROTEAN® Tetra Cell electrophoresis system and the Trans-Blot® SD SemiDry Electrophoretic Transfer Cell were purchased from Bio-Rad Laboratories (Hercules,
CA, USA). All other compounds used were of reagent grade.
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3.2 Generation of Plasmid Constructs

3.2.1 Wild-type hENTl Construct
The 1.35kb wild-type hENTl cDNA (in pcDNA3.1) was generously donated by
Dr. Ming Tse (Johns Hopkins University, Baltimore, MD) (92). The hENTl protein was
tagged with the FLAG epitope prior to use in this study. EcoRV and Kpnl restriction sites
were added to the 5’ and 3’ end o f the purified hENTl cDNA, respectively, using the
following primers: 5' EcoRV: 5'AGCGCGGATATCGATGACAACCAGT3' and 3' Kpn
I:

5'TAGCTAGG

TACCTCACACAATTGCCCG3'

(Sigma-Aldrich,

St.

Louis,

Missouri, USA). The p3xFLAG CMV-10 expression vector (Sigma-Aldrich, St. Louis,
Missouri, USA) was digested with Kpnl and EcoRV restriction enzymes (Fermentas,
Burlington, Ontario, Canada) at 37°C for 1 hr, then the hENTl cDNA was ligated into it
with a femtomolar vector/insert ratio o f 1:3, using the T4 DNA Ligase Kit (Invitrogen,
California, USA). The resulting expression plasmid, p3xFLAG-hENTl (N-terminal
epitope tag-DYKYYYD), was amplified and purified using the QIAprep® Spin Miniprep
Kit (Qiagen, Mississauga, ON, Canada) and confirmed by DNA sequencing at the
Robarts Research Institute Sequencing Facility.

3.2.2 Generation of PK15-hENTl Mutant Constructs
Single amino acid mutations within the p3XFLAG-hENTl template were created
with PCR using the Quikchange® II Site-Directed Mutagenesis kit (Stratagene,
California, USA). Primers containing the appropriate amino acid mutation were designed
and ordered from SigmaGenosys (Sigma-Aldrich, St. Louis, Missouri, USA). For each
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Primer Name

Sequence (5’ to 3’)

PK15-hENTl-G22A 5’

5’-CTTATCTTCTTCATGCTGGCTCTGGGAACGCTGCTC

PK15-hENTl-G22A 3 ’

5 ’-GAGCAGCGTTCCCAGAGCCAGCATGAAGAAGATAAG

PK15-hENTl-N81A 5’

5’CTCAGTGCCATCTTCGCCAATGTCATGACCCTA

PK15-hENTl-N81A 3 ’

5 ’-TAGGGTCATGACATTGGCGAAGATGGCACTGAG

PK15-hENTl-C87S 5’

5’-CAATGTCATGACCCTATCTGCC ATGCTGCCCCTGC

PK15-hENTl-C87S 3’

5 ’-GCAGGGGCAGCATGGCAGATAGGGTCATGACATTG

PK15-hENTl-T96A 5’

5’-CCCCTGCTGTTATTCGCCTACCTCAACTCCTTC

PK15-hENTl-T96A 3’

5 ’-GAAGGAGTTGAGGTAGGCGAATAACAGCAGGGG

PK15-hENTl-G163L 5’

5 ’-CCTGTTTCTTCTGGCTGGCCTTCTG

PK15-hENTl-G163L 3’

5 ’-CAGAAGGCCAGCCAGAAGAAACAGG

PK15-hENTl-G445L 5’

5 ’-GGTCTGGCACTGCTGGCTGTTTTCTCC

PK15-hENTl-G445L 3’

5 ’-GGAGAAAACAGCCAGCAGTGCCAGACC

Table 3.1 Forward (5’) and reverse (3’) mutation primers designed for site-directed
mutagenesis
All mutation primers were between 25-40 base pairs in length, had a GC content of 5060% and were o f PAGE purification grade. Primers were named by specifying the cell
line, species o f ENT and amino acid mutation made. Bases that are bolded and underlined
represent the mutation changes.
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sample reaction, a previously optimized concentration of 25 ng o f p3XFLAG- hENTl
template was added to 125 ng o f forward (5’) and reverse (3’) mutation primers each,
dNTPs, 10X reaction buffer, ddfbO and 1 pi of PfuUltra High-Fidelity DNA polymerase
(2.5U/pl). Sample reactions were overlaid with 30 pi of mineral oil, and then PCR was
conducted in a Perkin Elmer 480 thermal cycler with the following conditions: 30 s at
95°C (for 1 cycle); 30 s at 95°C, 1 min at 55°C and 8 min at 68°C (for 16 cycles). After
placing the reaction on ice for 2 min, 1 pi of Dpn I restricition enzyme (10 U/pl) was
added to each reaction and incubated at 37°C for 1 hour to digest parental dsDNA.
Transformation of XLl-Blue supercompetent cells was achieved by incubating 1
pi of amplified DNA product with 50pl o f XLl-Blue cells for 30 min on ice, heat pulsing
for 45 sec at 42°C and then ice for 2 min. NZY+ (0.5 ml) broth preheated to 42°C was
then added to the reactions and incubated with shaking at 250 rpm, at 37°C for 1 hour.
Two hundred and fifty pi of each transformation reaction was then plated on LBampicillin agar plates that contained 80 pg/ml X-gal and 20mM IPTG. The plates were
incubated at 37°C for at least 16 hours. Resulting colonies were picked, put into tubes
with 6 ml of Lennox Broth (LB) broth plus 6pl ampicillin (0.1 mg/ml) and shaken
overnight at approximately 250 rpm at 37°C. Plasmid DNA was purified from resulting
bacteria using the QIAprep® Spin Miniprep Kit (Qiagen, Mississauga, ON, Canada). To
confirm the presence of hENTl plasmid containing the desired mutation, the nucleotide
sequence of each plasmid was compared to the published nucleotide sequence of hENTl
(GenBank accession number: gi:1845345e). Sequencing was performed at the London
Regional Genomics Centre DNA Sequencing Facility, located in the Robarts Research
Institute (London, ON, Canada).
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3.2=3 Stable Transfection of PK15-NTD Cells
The Pig Kidney (PK15) cells were made nucleoside transport deficient (NTD) by
Ward et al. (92) by treating cells with the chemical mutagen, ethylmethanesulfonate. The
cells were then exposed to the cytotoxic nucleosides cytarabine (AraC) and tubercidin for
three weeks. Surviving cells were screened for the absence o f [ H]uridine uptake to
confirm that no es transporters were present. These PK15-NTD cells were generously
provided by Dr. Ming Tse (John Hopkins) for use in this study.
Confirmed mutant pcDNA 3.1 constructs were stably transfected into PK15-NTD
cells using LipofectAMINE™ 2000. One day prior to transfection, approximately 14 x l0 5 cells were plated in each well of a 12-well cell culture plate with MEM containing
no antibiotics. After ensuring that cells were 90-95% confluent on the day of transfection,
a previously optimized amount o f 1.6 pg plasmid DNA and 4.8 pi o f LipofectAMINE™
2000 were each separately diluted in Opti-MEM I Reduced Serum Medium and
incubated for 5 min. The DNA and LipofectAMINE™ 2000 mixtures were then
combined and incubated at room temperature for a further 20 min before being added to
the plated PK15-NTD cells. Plates were changed 18-48 hours after transfection to MEM
containing Geneticin® (G418) (0.5 mg/ml.). The vector pcDNA 3.1 provides resistance
to G418, allowing for the selection of transfected cells expressing the mutant plasmid.
Cells were kept under high G418 selection for 3 weeks, to eliminate cells not expressing
plasmid, and were then switched to MEM containing 0.3 mg/ml G418 for continued
maintenance o f the transfected cell line.
Cells were then cultured and moved to 6 well plates. In order to obtain a
homogenous population of cells, colonies with a density of approximately 300 cells
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grown from a single cell were transferred to a single well of a 24 well plate. This was
achieved by placing cloning cylinders around each colony with vacuum grease silicone to
ensure transfer o f the single colony. Six clones of each mutant plasmid cell line were
picked and gown to confluence. Stable cell lines were named according to the appropriate
mutant plasmid transfected, and clones of each mutant were labeled with a number (xl,
x2, x3 etc.) for accurate organization and characterization.
The stable transfection of cell lines was then confirmed by sequencing cDNA
prepared from RNA extraction and amplified by PCR, to ensure that any observed es
activity was a result o f the correct expression of the mutant plasmids. RNA was extracted
from cell pellets using TRIZOL® Reagent. RNA was reverse transcribed to first-strand
cDNA using the Superscript™ First Strand Synthesis System for RT (Reverse
Transcriptase) PCR. Amplification of resulting DNA was performed with Platinum® Pfx
DNA Polymerase under the following PCR conditions: 2 min at 94°C (to denature); 15 s
at 94°C, 30 s at 55°C, 1.5 min/kb at 68°C (for 35 cycles); 7 min at 68°C; then cooled at
4°C (primers used were hENTl 5’ GACAACCAGTCACCAGCCTCAGGACAG and hENTl
3’ CACACAATTGCCCGGAACAGGAAGGAG). PCR products were separated on a 1.0%
agarose gel, extracted using PureLink™ Quick Gel Extraction Kit (Invitrogen, California,
USA) and sequenced at the Robarts Research Institute Sequencing Facility. Clones of
mutant cell lines with confirmed sequences were subjected to a 6 point [3H]NBMPR
binding screen as an initial chracterization o f es transport. Clones with the greatest
difference between total and non-specific [3H]NBMPR binding were chosen for further
characterization.
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Cell lines were maintained at 37°C in a 5% CO 2 in a humidified atmosphere in
tissue culture flasks (T75 flasks for [3H]NBMPR binding; T175 flasks for [3H]2chloroadenosine uptake) in MEM containing 10% (v/v) bovine growth serum (BGS),
penicillin G (100 units/ml), streptomycin (100 pg/ml), sodium pyruvate (ImM),
nonessential amino acids (0.1 mM) and G418 (0.3 mg/ml). Cells were typically split 1:5
up to 60 passages and medium was replaced every 3-4 days.

3.3 Preparation of Cell Membranes
For cell membrane preparations, twelve T175 flasks were harvested with
0.05%Trypsin/0.53 mM EDTA and incubated in 5 mM Sodium Phosphate buffer
(Na2HPC>4 , pH 7.2) with a mammalian protease inhibitor cocktail (Calbiochem,
California, USA) for 20 min on ice. The cell suspension was sonicated for 30 s using a
Sonic Dismembrator model 150 (Thermo Fisher Scientific, Waltham, MA) until cloudy,
and then centrifuged at 3,000 g for 10 min at 4°C to pellet nuclei and unbroken cells. The
resulting supernatant was then centrifuged at 30,000 g for 30 min at 4°C. The pellet, i.e.
isolated membranes, was then suspended in 5mM Sodium Phosphate buffer and frozen in
lm L aliquots at -80°C. Protein concentrations were determined by the Bradford
colorimetric protein assay (Thermo Fisher Scientific, Waltham, MA). Isolated membrane
samples were used for [3H]NBMPR binding, inhibition of [3H]NBMPR binding, SDSPAGE and BNE experiments. Isolated membrane samples used for BNE were
additionally frozen with 10% (w/v) glycerol to prevent the denaturation of natively
associated protein complexes.
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3.4 [3H]NBMPR Binding
Cells were harvested by 0.05% (v/v) Trypsin/0.53 mM EDTA, 37°C, diluted with
MEM containing 10% (v/v) BGS, collected by centrifugation at 6,000g and washed twice
with Dulbecco’s phosphate-buffered saline (PBS; 137 mM NaCl, 6.3 mM Na 2HP 0 4 , 2.7
mM KC1, 1.5 mM KH2P 0 4, 0.5 mM MgCl2 • 6H20 , 0.9 mM CaCl • 2H20 , pH 7.4,
22°C). Approximately 8.0 x 104 cells were suspended in PBS and incubated with
increasing concentrations of [3H]NBMPR for 45 min at 22°C, to attain equilibrium. Cells
were incubated either in the absence (total) or presence (nonspecific) of 10 pM
nitrobenzylthioguanine riboside (NBTGR). Cells were then collected by vacuum on
Whatman Binder-Free Glass Micro fiber Filters: Type 934-AH, using a 24-port cell
harvester (Brandel) and washed twice with Tris buffer (10 mM Tris, pH 7.4, 4°C).
Samples were analyzed for [3H] content by standard liquid scintillation counting
techniques. Non-specific binding was defined as the remaining cell-associated
[3H]NBMPR in the presence of 10 pM NBTGR. Specific binding was defined as total
binding minus non-specific binding. Nonlinear regression was used to fit hyperbolic
curves (GraphPad Prism 4.03) of specific [3H]NBMPR binding against the free
concentration o f [ H]NBMPR, in order to determine IQ and Bmax values. Curves were
fitted using one-site specific binding based on the equation Y = Bmax*X/(iQ + X), where
Y= specific binding and X= radioligand concentration.

3.5 Inhibition of [3H]NBMPR Binding
Cells were incubated for 40 min with 0.5 nM [3H]NBMPR, along with an
increasing range o f the inhibitors dipyridamole, draflazine and dilazep. At the lowest
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concentration o f inhibitor, binding (at almost 100% of control) occurred and at the
highest concentration binding was mostly inhibited (binding is slightly above the
nonspecific component). Cells were filtered and processed as described above for the
[3H]NBMPR binding assays. IC 50 values obtained are the concentration of inhibitors that
produced a 50% decrease in site-specific [ HJNBMPR binding, after subtraction of the
nonspecific binding component. Kj values were calculated from these IC 50 values using
the Cheng-Prusoff equation: Kj= ICso/l+tLJ/Kd, where [L]= concentration of free
radioligand used and IQ= dissocation constant of the radioligand for the receptor (taken
from [3H]NBMPR binding data). Data were fitted using the one-site sigmoid doseresponse with variable slope model (GraphPad Prism 4.03), using the following equation:
Y=Bottom + (Top-Bottom)/(l+10A((LogIC50-X)*HillSlope)), where Y= % total binding
and X= logarithm concentration of the inhibitor. Top and bottom are the maximal and
minimal limits constrained to 100% and 0% of total site-specific binding, respectively.

3.6 [3H]2-chloroadenosine Uptake
To measure the capacity of hENTl variants for es transport, the uptake of [ H]2chloroadenosine was measured at room temperature (~ 22°C). Cells were suspended in
sodium-free NMG buffer (NMG; 140 mM NMG, 5 mM KC1, 4.2 mM KHCO 3, 0.36 mM
K 2HPO 4, 0.44 mM KH 2PO 4, 10 mM HEPES, 0.5 mM MgCl2, 1.3 mM CaCl2, pH 7.4,
22°C). Though these cells are not known to have any CNTs, sodium-free buffer was used
as a preventive measure to ensure that only Na+- independent equilibrative transport was
measured.

Approximately 1 x 10

cells in suspension were added to [ H]2-

chloroadenosine layered over a silicon:mineral (21:4 v/v) oil mixture. After 5 s
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incubation, uptake was terminated by centrifugation that sediments the cells through the
oil layer, providing effective separation from the substrate layer. The 5 s incubation was
pre-determined as the period that estimates the initial rate of uptake, by a time course
with PK15-hENTl cells. For time courses o f [ H]2-chloroadenosine uptake, cell
'i

suspensions were incubated over a time period o f 0 to 60 seconds with [ H]2chloroadenosine prior to termination by centrifugation. Cell pellets were then digested in
250pl 1 M sodium hydroxide (NaOH) overnight at room temperature and analyzed for
[3H]content by liquid scintillation counting. Uptake data are given as pmol/pl of
intracellular volume (pM) after correction for the amount of [ H] in the extracellular
space of the cell pellet. Total water volumes o f the cell pellets were determined by
■j

incubating the cells with [ HJwater for 3 min and processing the samples as described
above. The extracellular water volume was estimated from the amount of [ H]2chloroadenosine associated with the cell pellet using 3-5 s incubation times in the
presence o f supramaximal concentrations of ENT inhibitors. Curves were fitted using the
Michaelis-Menten equation: Y = Vmax*X/(Km + X), where Y= rate o f mediated uptake
and X= substrate concentration.

3.7 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
PK15-NTD cells (negative control) or PK15-NTD cells stably expressing
p3XFLAG-hENTl, p3XFLAG-hENTl mutants were plated on 2 x 10cm2 dishes and
grown to confluence. Plated cells were washed with cold sterile PBS and incubated with
IX lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1M EGTA, 1%
Triton, 2.5 mM sodium pyrophosphate, 1 mM p-glycerophosphate, 1 M NasVCU, and 1
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fig/ml leupeptin pH 7.5), including the serine protease inhibitor, lOmM PMSF
(phenylmethylsulfonyl fluoride) for 5 min on ice. Cells were then scraped, sonicated for
30 s using a Sonic Dismembrator model 150 (Thermo Fisher Scientific, Waltham, MA),
and centrifuged at 14,000xg for 10 min at 4°C to pellet nuclei and unbroken cells. Protein
concentrations of the resulting supernatants were determined by the Bradford protein
colorimetric assay. Fifty pg protein aliquots were mixed with IX SDS sample buffer (0.5
M Tris-Cl, pH 6.8, 30% glycerol, 10% SDS, 0.6 M dithiothreitol, and 0.0012%
bromophenol blue) and samples were frozen at -80°C. Prior to electrophoresis, samples
were denatured at 100°C for 5 min.
Samples were loaded onto 12% acrylamide gels (12% separating- dH20, 1.5M
Tris pH 8.8, 0.1% Sodium dodecyl sulfate (SDS), Bis-Acrylamide, 0.05% Ammonium
Persulfate (APS), 0.05% TEMED; 5% stacking- dH20, 0.5 M Tris pH 6.8, 0.1% SDS,
Bis-Acrylamide, 0.05% APS, 0.1% TEMED) and run at 150 V for approximately 1 hour,
using the Mini-PROTEAN® Tetra Cell electrophoresis system (Bio-Rad Laboratories,
Hercules, CA). After electrophoresis, gels were transferred to polyvinylidene fluoride
(PVDF) membranes using Towbin Transfer Buffer (2.5 mM Tris, 19.2 mM Glycine, 2%
Methanol) and the Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad
Laboratories, Hercules, CA), with the following conditions: 440 mA, limited to 20 V, for
2 hrs.
Membranes were blocked with 5% skim milk-TBST buffer (0.5 mM Tris, 13.8
mM NaCl, 2.7 mM KC1, 0.05% Tween-20) for 1 hr at room temperature and then
incubated with primary monoclonal mouse anti-FLAG Ab (1:2500 in 5% skim milkTBST) overnight at 4°C. Membranes were then washed 3 x 7 min with TBST and
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incubated with secondary goat anti-mouse Ab (1:25000 in 5% skim milk-TBST) for 45
min at room temperature. Membranes were then washed with TBST for 3 x 7 min,
incubated for 1 min with LumiGLO® chemiluminescent substrate (Cell Signaling
Technology, Danvers, Massachusetts) and imaged using the VersaDoc to detect any
FLAG-labeled protein. The molecular mass of each band o f interest was determined by
comparison to Precision Plus Protein™ Dual Colour Standards (Bio-Rad Laboratories,
Hercules, CA).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control to
verify the equal loading of samples. Blots were stripped for 2 x 10 min with a mild
stripping buffer (200 mM glycine, 1% Tween-20, and 0.1% SDS; pH 2.2), washed 2 x 1 0
min with Sterile PBS, 2 x 5 min with TBST and blocked with 5% skim milk-TBST for 1
hour at room temperature. Membranes were then re-probed with primary goat antiGAPDH Ab (1:1000 in 5% skim milk-TBST) overnight at 4°C. Blots were washed 3 x 7
min with TBST, incubated with secondary donkey anti-goat Ab (1:2000 in 5% skim
milk-TBST) for 45 min at room temperature, washed 3 x 7 min with TBST, incubated
with

LumiGlo

chemiluminescent

substrate

and

imaged

using

the

Molecular

Imager®VersaDoc™ 5000 MP System (Bio-Rad Laboratories, Hercules, CA).

3.8 Blue Native Electrophoresis (BNE)
Aliquots of isolated membranes were prepared and frozen at -80°C with 10%
(w/v) glycerol, as previously described. For samples that were treated by sodium
carbonate isolation, cells were harvested, sonicated and centrifuged at 3,000 g for 10 min
at 4°C in the same manner as described for the preparation of cell membranes. The
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supernatant was then added to sodium carbonate solution (100 mM, pH 11.0 at 4°C) and
incubated by stirring slowly for 1 hr at 4°C. Cell membranes were collected by
ultracentrifugation at 115,000 g for 1 hr at 4°C using a Beckman Coulter Optima™L-90K
Ultracentrifuge (Beckman Coulter, Mississauga, ON). Cell membranes treated with
sodium carbonate were then stored in the same manner as already described. Isolated
membrane samples were solubilized with lysis buffer (20 mM Tris-HCL, 0.1 mM EDTA,
500 mM e-aminocaproic acid, 10% glycerol, pH 7.0). The desired concentration o f non
ionic detergent was included along with the serine protease inhibitor, PMSF, before use.
Samples were incubated for 15 min and then centrifuged at 20,000 g for 20 min at 4°C to
pellet unlysed membranes and insoluble aggregates. To optimize the technique to our
protein o f interest, various concentrations and solubilization times of both Triton-XlOO
(TX-100) and n-Dodecyl-p-D-maltoside (DM) were tested. The specific solubilization
conditions used in each figure of the results section are indicated in the appropriate figure
legends. DM was chosen as the most suitable detergent due to previous work in our lab
with solubilization and functional reconstitution o f nucleoside transporters using
maltoside sugars (27). A more detailed explanation is provided in the discussion section.
Samples o f supernatant containing the solubilized membrane protein were then
resuspended in Coomassie Blue G250 sample buffer (500 mM e-aminocaproic acid, 100
mM Bistris, 5% Coomassie Blue G-250, pH 7.0).
Samples were loaded into pre-cast NativePAGE™ Novex® BisTris 4-16%
gradient native gels (Invitrogen, California, USA) and run with the XCell SurelLock™
Mini-Cell (Invitrogen, California, USA) electrophoresis system. The cathode chamber
was filled with Cathode Buffer A (50 mM Tricin, 15 mM Bistris, 0.02% Coomassie
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Brilliant Blue G-250, pH 7.0) and the anode chamber was filled with Anode Buffer (50
mM Bistris, pH 7.0). Gel electrophoresis was carried out at 4°C with the following
conditions: the voltage was set to 150V for 1 hr and was then increased to 250 V for the
remainder of the run, approximately 1.5 hrs. Cathode Buffer A was replaced with
Cathode Buffer B (50 mM Tricin, 15mM Bistris, pH 7.0) at approximately 1/3 of the way
through the run (30 min). Cathode Buffer B contains no Coomassie Blue G-250 and is
used to ensure that excess dye will not interfere with downstream immunostaining
techniques.
Gels were transferred to PVDF membranes using native blot buffer (20mM Tris,
150mM glycine, 0.02% SDS, 20% methanol) and the Trans-Blot® SD Semi-Dry
Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, CA) under the following
conditions: 440 mA, limit 20 V for 1 hour. Prior to immunoblotting, membranes were
stained with 0.1% (w/v) Ponceau S (in 5% (v/v) acetic acid) to visualize and note protein
markers o f the NativeMark™ Unstained Protein Standard (Invitrogen, California, USA),
and then rinsed with ddH20 to remove the Ponceau S stain. The R f (retardation factor)
values o f these protein markers were calculated and plotted against their known
molecular weights using a non-linear (second-order polynomial best-fit) model. This
calibration curve was used to estimate the molecular mass o f the ENT1 protein.
Immunoblotting procedures were performed as previously indicated. In addition to FLAG
Ab, blots were also stained directly for ENT1 protein using primary rabbit polyclonal
SLC29A1 Ab at a dilution of 1:200 in 5% skim milk-TBST for 2 hrs at room temperature
and secondary goat anti-rabbit Ab (1:20000 in 5% skim milk-TBST) for 1 hr at room
temperature.
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3.9 Immunofluorescence
One day prior to performing immunofluorescence, cells were plated to no more
than 75% confluence on sterile coverslips in 12 well plates. Coverslips were sterilized by
rinsing in 1% hydrochloric acid (HC1), dH20 and then 70% ethanol (EtOH). On the day
of imaging, cells were fixed with paraformaldehyde (PFA; 4% in PBS, pH 7.0), washed 2
x 5 min with PBS, permeabilized with TX-100 (0.25% in PBS), washed 2 x 5 min with
PBS and blocked with bovine serum albumin (BSA; 3% in PBS) for 1 hr at 37°C. Cells
were then incubated with primary monoclonal mouse anti-FLAG Ab (1:2000 in 3%
BSA/PBS) at 37°C, washed 3 x 5 min with PBS, incubated with secondary anti-mouse
IgG-FITC Ab (1:1000 in 3% BSA/PBS) at 37°C and washed for another 3 x 5 min with
PBS. Coverslips were mounted on slides in the dark using VECTASHIELD® Mounting
Medium with DAPI (Vector Labs, Burlington, ON, Canada) and cells were imaged with
the 1X81 Inverted Microscope (Olympus, Markham, ON). Slides were stored in the dark
at 4°C for future use.

3.10 Statistical Analysis
Data are presented as the mean ± standard error (S.E.) of n independent experiments
conducted in duplicate, unless otherwise stated. Curves were fitted using GraphPad Prism
4.03 software and data were statistically analysed using a two-way Student’s t-test, with
P<0.05 considered significant.
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CHAPTER 4. Results

4.1 Characterization of TM 1 and TM 2 Mutants of hENTl
The TM 1 and 2 residues N81, T96, G22 and C87 were targeted by site-directed
mutagenesis and assessed for their contributions to the functionality o f hENTl. This was
achieved by means o f [ H] NBMPR binding and [ H] 2-chloroadenosine uptake assays
designed to determine any differences in inhibitor and substrate affinities of the mutants
compared to wild-type hENTl.

4.1.1

[3H] NBMPR Binding and [3H] 2-chloroadenosine Uptake by wild-hENTl

transfected PK15-NTD cells
Wild-type hENTl transfected in PK15-NTD cells exhibited high affinity
reversible binding (K<j= 0.34 ± 0.03 nM) of the ENT 1-selective inhibitor, [3H] NBMPR
(Figure 4.1 A). This is comparable with the initial characterization of the cell line
performed by Ming Tse and colleagues (92), and is additionally consistent with other
models o f es transport that report high affinity [3H]NBMPR binding in the low nM range
(32, 39, 60, 25). The affinity, or the Km, of wild-type hENTl for [3H]2-chloroadenosine
uptake was 39 ± 3 pM (Figure 4.IB). Wild-type hENTl had a Bmax of 450 ± 28 x 103
sites/cell (Figure 4.1 A) and a Vmax of 6.2 ± 0.7 pmol/pl/s (Figure 4 .IB). Bmax and Vmax
values represent the number of ENT 1 binding sites/cell and the maximal rate of mediated
uptake of substrate into the cell, respectively. These values are subject to the transfection
efficiency o f creating stable cell lines. Ratios can be calculated in order to determine

Figure 4.1 Summary of wild-type hENTl (A) [3H]NBMPR binding and (B) [3H]2chloroadenosine uptake
A) The amount o f bound [3H]NBMPR was plotted against the free concentration of
[3H]NBMPR at equilibrium. [3H]NBMPR binding was assessed by incubating cell
suspensions with increasing concentrations of [3H]NBMPR in the presence (nonspecific
binding) or absence (total binding) of 10 pM NBTGR. Specific binding was determined
as the difference between total binding and nonspecific binding. Each point represents the
mean ± SEM from thirty-five independent experiments, each done in duplicate.
B) The uptake of [ H]2-chloroadenosine into cells during a 5 second incubation was
•3

___

plotted against increasing concentrations of [ H]2-chloroadenosine. Transporter mediated
uptake (pmol/pl/s) was defined as the total uptake minus non-mediated uptake. Nonmediated uptake was measured in the presence of 10 pM NBMPR + 10 pM
dipyridamole. Each point represents the mean ± SEM from thirty-one independent
experiments.

Binding (ENTi/cell)

A. [3H]NBMPR binding

B. [3H]2-chloroadenosine uptake
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whether a change in these values is actually due to the mutation being made or a result of
transfection efficiency. Such data analyses are presented in the appropriate tables in the
results section, but an in-depth explanation of these ratios will be addressed in the
discussion section.
Radioligand binding assays measure two conditions: total binding and nonspecific
•5

^ __

___

binding, that is, any [ HJNBMPR not bound to ENT1. These data are then transformed by
subtracting the nonspecific background from the total binding to provide a measure of the
ENT1-specific binding o f [ HJNBMPR (Figure 4.1 A). The same treatment is applied to
the raw data obtained from radiolabeled substrate experiments. The ENT 1-mediated
uptake of [3H]2-chloroadenosine into cells is quantified by subtracting the nonmediated
uptake from the total uptake (Figure 4. IB). All data presented in this thesis has thus been
adjusted accordingly, such that the resultant figures represent the specific binding and
transporter-mediated uptake by the wild-type and mutant hENTl transporters under
investigation.
Immunfluorescence (IF) of wild-type hENTl (Figure 4.2) was additionally
undertaken to assess the distribution of ENT 1 within the PK15 cell, more specifically, to
differentiate transporter protein within the intracellular compartment of the cell versus at
the plasma membrane. IF of PK15-NTD cells (negative control) contained no green
fluorescence, indicative of a lack of FLAG-tagged ENT1 protein. Green fluorescent
FLAG-tagged ENT1 protein was observed in wild-type hENTl cells, mostly within the
intracellular compartment of the cell. Due to the strong presence of intracellular hENTl,
the plasma membrane localization of the transporter was not clearly defined. An
interpretation of these findings will be addressed in the discussion.

Figure 4.2 Immunofluorescence of (A) PK15-NTD cells and (B) wt hENTl cells
Cells were plated on coverslips, fixed with 4% paraformaldehyde (PFA) and then
permeabilized with 0.25% TritonX-100 (TX-100). Fixed cells were then probed with
primary Anti-FLAG Ab followed by secondary rabbit anti-mouse IgG FITC Ab. Cells
were then stained with DAPI and imaged using fluorescence microscopy. The green
fluorescence observed is FLAG-tagged ENT1 protein and blue fluorescence is the
nuclear DAPI stain.
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A. PK15-NTD

B. Wild type hENTl
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4.1.2 PK15-hENTl-N81A
The PK15-hENTl-N81A cells (Figure 4.3A) possessed a significantly
weaker affinity than wild-type hENTl, with a IQ of 1.0 ± 0.2 nM, for the binding of
[3H]NBMPR (P<0.05) (Table 4.1). There was no significant difference in the number of
ENTI binding sites/cell (Table 4.1) of PK15-hENTl-N81A compared to wild-type
hENTl (P>0.05). Isolated membrane preparations of PK15-hENTl-N81A (Figure 4.3B)
showed a similar decrease in affinity for [ HJNBMPR as that observed in PK15-hENTlN81A cells. However, in contrast to the whole cell binding data, there was a large drop in
the ENTl-specific binding o f PK15-hENTl-N81A (0.61 ± 0.08 pmol/mg) compared to
wild-type hENTl (2.3 ± 0.01 pmol/mg) (Table 4.1). The initial rate of mediated uptake of
[3H]2-chloroadenosine (Fig. 2) by PK15-hENTl-N81A (6.1 ± 0.3 pmol/pl/s) is also
significantly slower than the rate of mediated uptake exhibited by wild-type hENTl (10 ±
3 pmol/pl/s) (P<0.05). There was no difference in the Km o f [3H]2-chloroadenosine
uptake (P>0.05) (Table 4.1).
Based on the change in affinity of PK15-hENTl-N81A for [3H]NBMPR binding,
the competitive inhibition of [3H]NBMPR by dipyridamole, draflazine and dilazep
(Figure 4.5) was assessed for potential changes in the sensitivity of PK15-hENTl-N81A
to other inhibitors. There was no significant change in the sensitivity of PK15-hENTlN81A for dipyridamole compared to wild-type hENTl (P>0.05) (Table 4.2). PK15hENTl-N81A did, however, show a significantly reduced sensitivity to the inhibitor
draflazine in both whole cells (N81A Ki= 6.6 ± 1 .3 nM; w.t. hENTl Kj= 2.4 ± 0.5 nM)
and isolated membranes (N81A Kj= 1.8 ± 0.5 nM; w.t. hENTl Ki= 0.40 ± 0.08 nM)
(P<0.05) (Table 2). There was also a significantly reduced sensitivity of isolated

Figure 4.3 [3H]NBMPR binding to wild-type hENTl and PK15-hENTl-N81A in (A)
Whole cells and (B) Isolated membranes
[3H]NBMPR binding was assessed by incubating cell suspensions with increasing
concentrations of [ HJNBMPR in the presence (nonspecific binding) or absence (total
binding) of 10 pM NBTGR. Nonlinear regression analysis was used to fit hyperbolic
curves to the site-specific binding of [3H]NBMPR plotted against the free concentration
of [ H]NBMPR at equilibrium. Specific binding was determined as total binding minus
nonspecific binding. Each point represents the mean ± SEM from six independent
experiments, each done in duplicate.
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Figure 4.4 Concentration-dependent uptake of [3H]2-chloroadenosine by wild-type
hENTl and PK15-hENTl-N81A mutant cells
The initial rate of transporter-mediated uptake of [3H]2-chloroadenosine estimated using
a 5 second incubation was plotted against increasing concentrations o f [3H]2chloroadenosine. Transporter-mediated uptake (pmol/pl/s) was defined as the total uptake
minus non-mediated uptake. Non-mediated uptake was measured in the presence of 10
pM NBMPR + 1 0 pM dipyridamole. Each point represents the mean ± SEM from five
independent experiments.
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Whole Cells
Kd(nM)

Bmax

Km (pM)

(sites/cell)

^max
(pmol/pl/s)

Wt hENTl

0.36 ±0.08

476 ± 65 x 103

54 ± 13

10 ± 3

PK15hENTl-N81A

1.0 ± 0 .2 *

581 ± 6 5 x 103

40 ± 6

6.1 ±0.3*

w.t.Bmax/N81AB max
0.8 ± 0.2

Isolated M embranes

Kd(nM)

-‘-'max

(pmol/mg)
W thE N T l

0.12 ±0.01

2.3 ±0.01

PK15hENTl-N81A

0.36 ± 0.03*

0.61 ±0.08*

w.t.Bmax/N81AB max
3.7 ±0.1
*Significantly different from the corresponding value for wt hENTl (P<0.05, Students ttest)

Table 4.1 Analysis of [3H]NBMPR binding and [3H]2-chloroadenosine uptake by
PK15-hENTl-N81A cells
Parameters o f [3H]NBMPR binding, derived from data shown in Figure 4.3, and [3H]2chloroadenosine uptake, derived from data shown in Figure 4.4, were determined from
fitting hyperbolic curves to the specific [ H] NBMPR binding or the specific [ H] 2chloroadenosine uptake data of each experiment. K<i and Bmax values of whole cell and
membrane binding are both the mean± SEM of six experiments, performed in duplicate.
Km and V max values are the mean ± SEM of five independent experiments.

Figure 4.5 Inhibition of [3H]NBMPR binding to wild-type hENTl and PK15hENTl-N81A cells and isolated membranes by (A) Dipyridamole, (B) Draflazine
and (C) Dilazep
Inhibition of 0.5 nM [3H]NBMPR binding was evaluated in the presence o f increasing
concentrations of the inhibitors dipyridamole, draflazine and dilazep. The amount of
specific [3H]NBMPR binding at equilibrium was plotted against the log o f the inhibitor
concentration. Data is shown as the percent of ‘total’ [3H]NBMPR binding, with ‘total’
binding being the specific binding of 0.5 nM [3H]NBMPR in the absence o f any inhibitor.
Each point represents the mean ± SEM o f at least five individual experiments, each
performed in duplicate.
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Ki(nM)

nH

Whole Cell
wt hENTl (6)
PK15-hENTl-N81A (6)

32 ± 10
20 ± 4

-1.2 ±0.2
-0.9 ±0.1

Isolated Membranes
wt hENTl (8)
PK15-hENTl-N81A (8)

73 ± 7
98 ± 14

-1.0 ±0.1
-0.6 ± 0.2*a

Whole Cell
wt hENTl (7)
PK15-hENTl-N81A (7)

2.4 ± 0.5
6.6 ±1.3*

-1.1 ±0.2
-1.1 ±0.1

Isolated Membranes
wt hENTl (5)
PK15-hENTl-N81A (5)

0.40 ± 0.08
1.8 ±0.5*

-1.6 + 0.3a
-0.87 ± 0.1 l* a

Whole Cell
wt hENTl (6)
PK15-hENTl-N81A (6)

3.9 ± 1.3
5.3 ± 1.4

-1.3 ±0.3
-1.2 ±0.2

Isolated Membranes
wt hENTl (5)
PK15-hENTl-N81A (5)

0.56 ±0.19
3.6 ±0.6*

-1.05 ±0.07
-0.77 ± 0.04*a

Cell Preparation (n)

Inhibitor
Dipyridamole

Draflazine

Dilazep

*Significantly different from the corresponding value for wt hENTl (P<0.05, Students ttest)
a Hill slope (nH) significantly different from unity (P<0.05, Students t-test)
Table 4.2 Inhibition of [3H]NBMPR binding to wt hENTl and PK15-hENTl-N81 A
[3H]NBMPR binding was measured in the presence of increasing inhibitor concentrations
and the resulting data was fitted to sigmoid dose-response curves. IC50 values obtained
were used to determine K\ values with the equation o f Cheng-Prusoff: Ki = IC50 /
1+([S]/Kd). Pseudo Hill coefficients (nH) were taken from the slopes of the sigmoid
curves. Each value is the mean ± SEM of the indicated number of experiments (n),
performed in duplicate.
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membrane preparations o f PK15-hENTl-N81A to dilazep (N81A Ki= 3.6 ± 0.6 nM; w.t.
hENTl Kj= 0.6 ± 0.2 nM) (P<0.05) (Table 4.2). Although there was a slight trend
towards the same in whole cells, there was no significant change in dilazep sensitivity of
PK15-hENTl-N81A cells (P>0.05). All inhibition profiles with membrane preparations
of PK15-hENTl-N81A consistently showed a significant deviation from a Hill slope
(nH) of -1 that was not mirrored in wild-type hENTl membrane preparations. The nH
values o f PK15-hENTl-N81A membranes for dipyridamole, draflazine and dilazep
inhibition were -0.6 ± 0.2, -0.9 ± 0.1 and -0.8 ± 0.04, respectively (P<0.05) (Table 4.2).
This difference was not observed in inhibition profiles carried out with whole cells,
which were not significantly different from unity (P>0.05).

4.1.3 PK15-hENTl-T96A
The mutant PK15-hENTl-T96A exhibited high affinity [3H]NBMPR binding
that was similar in affinity to wild-type hENTl (Figure 4.6). There was a significant
difference in ENT1-specific binding in PK15-hENTl-T96A whole cells (T96A Bmax=
130 ± 9 x 103 sites/cell; w.t. hENTl Bmax= 377 ± 54 x 103 sites/cell) and likewise, in
membranes (T96A Bmax= 1-8 ± 0.1 pmol/mg; w.t. hENTl Bmax= 2.8 ± 0 .1 pmol/mg)
(P<0.05) (Table 4.3). Although PK15-hENTl-T96A was not substantially different from
wild-type hENTl in terms of [3H]NBMPR binding affinity, there was a significant
increase in the Km o f [3H]2-chloroadenosine uptake of PK15-hENTl-T96A (50 ± 5 pM)
compared to wild-type hENTl (32 ± 6 pM) (P<0.05) (Figure 4.7) (Table 4.3). There was
no difference in the rate of mediated uptake o f [ H]2-chloroadenosine by wild-type
hENTl and PK 15-hENT 1-T96A cells (P>005) (Table 4.3).

Figure 4.6 [3H]NBMPR binding to wild-type hENTl and PK15-hENTl-T96A in (A)
Whole cells and (B) Isolated membranes
[3H]NBMPR binding was assessed by incubating cell suspensions with increasing
concentrations o f [3H]NBMPR in the presence (nonspecific binding) or absence (total
binding) of 10 pM NBTGR. Nonlinear regression analysis was used to fit hyperbolic
curves to the site-specific binding of [3H]NBMPR plotted against the free concentration
of [3H]NBMPR at equilibrium. Specific binding was determined as total binding minus
nonspecific binding. Each point represents the mean ± SEM from five (whole cell) and
four (membranes) independent experiments done in duplicate.

A. Whole Cells

B. Isolated Membranes

Figure 4.7 Concentration-dependent uptake of [3H]2-chIoroadenosine by wild-type
hENTl and PK15-hENTl-T96A cells
The initial rate of transporter-mediated uptake of [3H]2-chloroadenosine estimated using
a 5 second incubation was plotted against increasing concentrations o f [ H]2chloroadenosine. Transporter-mediated uptake (pmol/pl/s) was defined as the total uptake
minus non-mediated uptake. Non-mediated uptake was measured in the presence o f 10
pM NBMPR + 1 0 pM dipyridamole. Each point represents the mean ± SEM from seven
independent experiments.
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Whole Cells
Kd(nM)

Bmax

Km(pM)

(sites/cell)

Vmax

(pmol/pl/s)

Wt hENTl

0.30 ± 0.08

377 ± 54 x 103

32 ± 6

3.5 ±0.2

PK15hENTl-T96A

0.19 ±0.02

130 ± 9 x 103*

50 ± 5*

3.1 ±0.5

w.t.Bmax/N81AB max
2.9 ±0.2

Isolated M embranes
Kd(nM)

Bmax

(pmol/mg)
Wt hENTl

0.10 ±0.002

2.8 ±0.1

PK15hENTl-T96A

0.10 ±0.006

1.8 ± 0.1*

w.t.Bmax/N81AB;
1.6 ± 0.1
*Significantly different from the corresponding value for wt hENTl (P<0.05, Students ttest)
Table 4.3 Analysis of [3H]NBMPR binding and [3H]2-chloroadenosine uptake by
PK15-hENTl-T96A cells
Parameters o f [3H]NBMPR binding, derived from data shown in Figure 4.6, and [3H] 2chloroadenosine uptake, derived from data shown in Figure 4.7, were determined from
fitting hyperbolic curves to the specific [ HJNBMPR binding or the specific [ H]2chloroadenosine uptake data of each experiment. Kd and Bmax values o f whole cell and
membrane binding are the mean± SEM o f five and four individual experiments
performed in duplicate, respectively. Km and Vmax values are the mean ± SEM of seven
independent experiments.
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4.1.4 PK15-hENTl-G22A
Initial studies of PK15-hENTl-G22A with regards to [3H]NBMPR binding
(Figure 4.8) in cells indicated a significant decrease in affinity (G22A K<j= 1.1 ± 0.20 nM;
w.t. hENTl K<j= 0.32 ±0.11 nM) as well as a decrease in the number of ENT 1-specific
binding sites (G22A Bmax= 36 ± 10 x 103 sites/cell; w.t. hENTl Bmax= 373 ± 76 x 103
sites/cell) compared to wild-type hENTl (P<0.05) (Table 4.4). To mimic the dramatic
decrease in number of ENT1 binding sites observed, there was an equally dramatic
decrease in the initial rate of mediated uptake of [ H] 2-chloroadenosine uptake (Figure
4.9), with PK15-hENTl-G22A having a Vmax of 0.6 ±0.1 pmol/pl/s compared to the rate
of 4.1 ± 0.5 pmol/pl/s observed by wild-type hENTl (PO .05) (Table 4.4).
These data sets were performed in November 2009. Cells were then frozen at 80°C, thawed at a later date and used for the preparation of isolated membranes. Assays
performed with the resulting membrane samples showed no measurable specific
[3H]NBMPR binding, with binding levels typical of nonspecific binding (Figure 4.10).
Subsequently, a whole cell [3H]NBMPR binding assay carried out with these newly
thawed PK15-hENTl-G22A cells confirmed that, with a resultant 1,387 binding
sites/cell, PK15-hENTl-G22A was no longer detectable.

4.1.5 PK15-hENTl-C87S
PK15-hENTl-C87S displayed properties that were mainly comparable to the
characteristics o f wild-type hENTl in terms of both [3H]NBMPR binding (Figure 4.11)
and [ H]2-chloroadenosine uptake (Figure 4.12). There was no significant difference in

Figure 4.8 [3H]NBMPR binding to wild-type hENTl and PK15-hENTl-G22A cells
[3H]NBMPR binding was assessed by incubating cell suspensions with increasing
concentrations o f [3H]NBMPR in the presence (nonspecific binding) or absence (total
binding) o f 10 pM NBTGR. Nonlinear regression analysis was used to fit hyperbolic
curves to the site-specific binding o f [3H]NBMPR plotted against the free concentration
of [3H]NBMPR at equilibrium. Specific binding was determined as total binding minus
nonspecific binding. Each point represents the mean ± SEM from four independent
experiments performed in duplicate. Due to the low expression o f the mutant, an
expanded view of the PK15-hENTl-G22A and PK-15 NTD data is additionally
presented.

Specific Bound (ENT1/cell)
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Figure 4.9 Concentration-dependent uptake of [3H]2-chIoroadenosine by wild-type
hENTl and PK15-hENTl-G22A cells
The initial rate of transporter-mediated uptake o f [3H]2-chloroadenosine estimated using
a 5 second incubation was plotted against increasing concentrations o f [ H]2chloroadenosine. Transporter-mediated uptake (pmol/pl/s) was defined as the total uptake
minus non-mediated uptake. Non-mediated uptake was measured in the presence o f 10
pM NBMPR + 1 0 pM dipyridamole. Each point represents the mean ± SEM from six
independent experiments.
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Figure 4.10 [3H]NBMPR binding to isolated membranes of wild-type hENTl and
PK15-hENT 1-G22 A
[3H]NBMPR binding was assessed by incubating isolated membrane suspensions with
increasing concentrations o f [3H]NBMPR in the presence (nonspecific binding) or
absence (total binding) o f 10 pM NBTGR. Nonlinear regression analysis was used to fit
hyperbolic curves to the site-specific binding o f [3H]NBMPR plotted against the free
concentration of [3H]NBMPR at equilibrium. Specific binding was determined as total
binding minus nonspecific binding. Each point represents the mean ± SEM from four
independent experiments performed in duplicate.
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Whole Cells
Kd(nM)

Bm ax

Km(pM)

(sites/cell)

V m aX

(pmol/pl/s)

Wt hENTl

0.32 ±0.11

373 ± 76 x 103

41 ± 7

4.1 ±0.5

PK15hENTl-G22A

1.1 ±0.2*

36 ± 10 x 103*

41 ± 11

0.6 ±0.1*

*Significantly different from the corresponding value for wt hENTl (P<0.05, Students ttest)

Table 4.4 Analysis of [3H]NBMPR binding and [3H]2-chloroadenosine uptake by
PK15-hENTl-G22A cells
Parameters o f [3H] NBMPR binding of whole cells (Figure 4.8) and membranes (Figure
4.10), as well as [3H]2-chloroadenosine uptake (Figure 4.9), were determined from fitting
hyperbolic curves to the specific [3H]NBMPR binding or the specific [3H]2chloroadenosine uptake data of each experiment. K<j and Bmax values of both whole cell
and membrane binding are the m eant SEM of four individual experiments performed in
duplicate. Km and Vmax values are the mean ± SEM of six independent experiments.
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the affinity for NBMPR o f PK15-hENTl-C87S when compared to wild-type hENTl
(P>0.05) (Table 4.5). There was a significant difference in the number of ENT 1-specific
binding sites of PK15-hENTl-C87S in cells (C87S Bmax= 144 ± 12 x 103 sites/cell; w.t.
hENTl Bmax= 417 ± 43 x 103 sites/cell) as well as membranes (C87S Bmax= 0.71 ± 0.05
pmol/mg; w.t. hENTl Bmax= 1.5 ± 0.2 pmol/mg) (P<0.05) (Table 4.5). Data presented in
this thesis on [3H] NBMPR binding to isolated membranes prepared from PK15-hENTlC87S cells are credited to Jamie Park. In terms of the kinetic parameters of [3H]2chloroadenosine uptake there was no observable difference in Vmax of PK15-hENTlC87S and wild-type hENTl (P>0.05). There was a slight but significant increase in
affinity o f PK15-hENTl-C87S compared to wild-type hENTl (C87S Km= 27 ± 2 pM;
w.t. hENTl Km= 34 ± 4 pM) (P<0.05) (Table 4.5).

4.1.6 Protein Electrophoretic Mobility of the TM 1 and 2 Mutants
To confirm the molecular mass of hENTl under reducing conditions, isolated
membranes o f wild-type hENTl and TM 1 and 2 mutants were separated by SDS-PAGE
(Figure 4.13). Resulting immunoblots were probed with anti-FLAG Ab and bands
corresponding to FLAG-tagged protein were visualized at 55 kDa, which is consistent
with the known molecular mass of hENTl. There was an additional band at
approximately 25 kDa that is most likely a degradation product.

Figure 4.11 [3H]NBMPR binding to wild-type hENTl and PK15-hENTl-C87S in
(A) Whole cells and (B) Isolated membranes
[3H]NBMPR binding was assessed by incubating cell suspensions with increasing
concentrations o f [ HJNBMPR in the presence (nonspecific binding) or absence (total
binding) of 10 pM NBTGR. Nonlinear regression analysis was used to fit hyperbolic
curves to the site-specific binding o f [ HJNBMPR plotted against the free concentration
of [3H]NBMPR at equilibrium. Specific binding was determined as total binding minus
nonspecific binding. Each point represents the mean ± SEM from twelve (whole cell) and
four (membranes) independent experiments done in duplicate.

Specific Bound (ENTi/cell)

A. Whole Cells

B. Isolated Membranes

Figure 4.12 Concentration-dependent uptake of [3H]2-chloroadenosine by wild-type
hENTl and PK15-hENTl-C87S cells
The initial rate o f transporter-mediated uptake of [3H]2-chloroadenosine estimated using
a 5 second incubation was plotted against increasing concentrations o f [ H]2chloroadenosine. Transporter-mediated uptake (pmol/pl/s) was defined as the total uptake
minus non-mediated uptake. Non-mediated uptake was measured in the presence o f 10
pM NBMPR + 1 0 pM dipyridamole. Each point represents the mean ± SEM from fifteen
independent experiments.
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Whole Cells
Kd(nM)

Bmax

Km (pM)

(sites/cell)

^max

(pmol/pl/s)

W thE N T l

0.41 ± 0.06

417 ± 43 x 103

34 ± 4

6.5 ± 0.7

PK15hENTl-C87S

0.30 ± 0.06

144 ± 12 x 103*

27 ± 2 *

6.4 ± 0.4

w.t.Bmax/N81AB max
2.9 ± 0.1

Isolated M embranes
Kd ( llM )

Bmax

(pmol/mg)
W thE N T l

0.14 ±0.02

1.5 ± 0.2

PK15hENTl-C87S

0.19 ± 0.04

0.71 ± 0.05*

w.t.Bmax/N81AB max

2.1 ± 0.1
*Significantly different from the corresponding value for wt hENTl (P<0.05, Students ttest)
Table 4.5 Analysis of [3H]NBMPR binding and [3H]2-chloroadenosine uptake by
PK15-hENTl-C87S cells
Parameters o f [3H]NBMPR binding of whole cells and membranes (Figure 4.11), as well
as [3H]2-chloroadenosine uptake (Figure 4.12), were determined from fitting hyperbolic
curves to the specific [3H]NBMPR binding or the specific [3H]2-chloroadenosine uptake
data of each experiment. Kd and Bmax values of both whole cell and membrane binding
are the mean± SEM of twelve and four individual experiments performed in duplicate,
respectively. Km and Vmax values are the mean ± SEM of fifteen independent
experiments.

Figure 4.13 Immunoblots of TM 1 and TM 2 hENTl Mutants
Aliquots of isolated PK-15 NTD (Nucleoside Transport deficient), wt hEN Tl, PK15hENTl-G22A,

PK15-hENTl-N81A

and

PK15-HENT1-T96A

membranes

were

solubilized in IX lysis buffer. 50 fig protein aliquots o f supernatant were resuspended in
6X sample buffer and then run on denaturing 12.5% acrylamide gels. The molecular
marker to the left o f the figure is based on the Precision Plus Protein Dual Colour
Standards ladder. After transfer, immunoblots were probed with primary Anti- FLAG Ab.
The image shown is a representative blot of n=3.
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4.2 Oligomerization of hENTl

4.2.1 Blue Native Electrophoresis (BNE)
Blue Native Electrophoresis was used as an initial assessment of the native state
of hENTl. In order to optimize the technique to the native separation of hENTl protein,
various detergents and solubilizing conditions were tested to ensure the mildest, most
efficient separation of protein. First, to establish the appropriate amount of protein to
load, isolated membrane preparations of FLAG-tagged wild-type hENTl

were

solubilized in 1.0% Triton X-100 detergent then centrifuged at 14,000xg for 15 minutes
at 4°C. Five jug, 10 pg and 25 pg samples o f solubilized protein were loaded, with
subsequent immunoblotting using primary Anti-FLAG Ab (Figure 4.14A). These studies
indicated that 10 pg produced a suitable signal for future work. Based on the calibration
curve made from the NativeMark Unstained Protein Ladder (Figure 4.14C), wild-type
hENTl has a native molecular mass of approximately 130 kDa. The blot was then
stripped and re-probed with primary SLC29A1 ENT1 Ab (Figure 4.14B), confirming that
the visualized band corresponds to ENT1.
Dodecylmaltoside (DM) was also tested as a candidate for hENTl solubilization
and was chosen as the detergent of choice for further work. This decision was based on
previous ENT1 solubilization and functional reconstitution studies in the lab of Dr. J.R.
Hammond (27) and will be addressed in detail in the discussion. As a test to determine
the most appropriate detergent concentration to use, wild-type hENTl membrane protein
samples were incubated with increasing DM concentrations (0.05% - 10%). The native
gel was then electrophoresed using Coomassie Blue G250 Cathode Buffer and de-stained

Figure 4.14 Blue Native Electrophoresis of wt hENTl; Immunoblot probed with (A)
primary FLAG Ab (B) primary SLC29A1 Ab (C) Calibration curve of NativeMark
Unstained Protein Ladder
An aliquot of isolated wt hENTl membranes was solubilized in 1.0% Triton X-100
detergent and resuspended in Coomassie Blue G250 sample buffer. Samples o f 5, 10 and
25 pg were resolved on a 4-16% Native BisTris gradient gel. After transfer, immunoblots
were probed with primary Anti- FLAG Ab, stripped and re-probed with primary ENT1
Ab. The image shown is a representative blot o f n=3. R f values determined from the
NativeMark Unstained Protein Ladder were used to generate a calibration curve o f
Molecular Weight (kDa) plotted against R f value, in order to predict the molecular
weight of bands of interest.
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A. 1° Flag Ab

B. 1° SLC29A1 Ab

1048kDa---- 1
720kDa —
480kDa----

242kDa —
146kDa—
66kDa—

20kDa

C. NativeMark Protein Ladder Calibration Curve

Rf 0.60

M.W.= 130 kDa
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(Figure 4.15). There was comparable protein separation in all concentrations of DM used,
with higher concentrations of DM degrading samples. Therefore, the lowest commonly
used concentration of 0.2% DM was chosen to ensure the mildest solubilization
conditions. Another initial concern was that storage of samples at -80°C, despite the
addition of 10% (w/v) glycerol, would affect native protein complex associations. There
was no difference in the molecular mass of wild-type hENTl samples prepared fresh and
samples stored at -80°C when analyzed by BNE (Figure 4.16).
To test the possible impact of PK15-hENTl-N81 on hENTl oligomerization, a
residue potentially involved as an asparagine pair in helical packing, samples of PK15hENTl-N81 A membranes were analyzed with BNE (Figure 4.17). Aliquots of isolated
membrane preparations were solubilized with 0.2% DM for either 15 or 30 minutes and
centrifuged at 20,000xg for 20 minutes at 4°C. Ten pg samples o f supernatant, which
contained solubilized protein, were then resolved on a native gradient gel. Based on the
NativeMark ladder calibration curve (Figure 4.17C), the immunoblot with primary AntiFLAG Ab (Figure 4.17A) showed that hENTl has a molecular weight of approximately
126 kDa. PK15-hENTl-N81A has the same molecular mass as wild-type hENTl when
resolved with BNE. This blot was also stripped and re-probed with ENT1 Ab (Figure
4.17B). Bands of the same molecular weight were observed as with the FLAG Ab.

4.2.2 Functional Characterization of the GxxxG Mutants: PK15-hENTl-G163L and
PK15-hENTl-G445L
An initial [3H]NBMPR binding screen of a number of PK15-hENTl-G163L and
PK15-hENTl-G445L clones revealed that while the PK15-hENTl-G163L mutant was

Figure 4.15 Solubilization test of n-Dodecyl (J-D-maltoside (DM)
Separate aliquots o f wild type hENTl membranes were solubilized with a range o f
increasing concentrations o f DM (0.05- 10%) for 15 minutes and then resuspended in
Coomassie Blue G250 sample buffer. 10 pg samples were loaded onto a 4-16% Native
BisTris gradient gel and the run was completed without the Blue Cathode Buffer to its
colourless alternative, in order to stain the gel blue. The gel was then destained until
protein bands were visible and imaged. 7 pg NativeMark Unstained Protein Ladder was
loaded and is visible on the left hand side of the figure.
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Figure 4.16 Blue Native Electrophoresis of fresh and frozen aliquots of w t hE N T l;
(A) Im munoblot probed with prim ary FLAG Ab (B) C alibration curve of
NativeM ark Unstained Protein L adder
Aliquots of isolated wt hENTl membranes that were either frozen at -80°C or prepared
on the same day were solubilized in 0.2% DM and resuspended in Coomassie Blue G250
sample buffer. Samples of 10 pg were resolved on a 4-16% Native BisTris gradient gel.
After transfer, immunoblots were probed with primary Anti- FLAG Ab. The image
shown is a representative blot of n=3. R f values determined from the NativeMark
Unstained Protein Ladder were used to generate a calibration curve of Molecular Weight
(kDa) plotted against R f value, in order to predict the molecular weight of bands of
interest.
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Figure 4.17 Blue Native Electrophoresis of wt hE N T l and PK 15-hEN Tl-N81A;
Im munoblot probed with (A) prim ary FLAG Ab (B) p rim ary SLC29A1 Ab (C)
C alibration curve of N ativeM ark Unstained Protein L adder
An aliquot of isolated PK-15 NTD (Nucleoside Transport deficient), wt hENTl and
PK15-hENTl-N81A membranes was solubilized in 0.2% n-Dodecyl P-D-maltoside
detergent for either 15 min or 30 min and resuspended in Coomassie Blue G250 sample
buffer. Samples of 10 pg were run on a 4-16% Native BisTris gradient gel. After transfer,
immunoblots were probed with primary Anti- FLAG Ab, stripped and re-probed with
primary ENT1 Ab. R f values determined from the NativeMark Unstained Protein Ladder
were used to generate a calibration curve o f Molecular Weight plotted against R f value,
in order to predict the molecular weight o f bands of interest.
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capable o f binding NBMPR (Figure 4.18A), the PK15-hENTl-G445L was not (Figure
4.18B).

An immunoblot of PK15-hENTl-G163L clones (Figure 4.18A) probed with

primary FLAG Ab further confirmed the presence of PK15-hENTl-G163L protein. The
appearance of smudged bands immediately above and below the 55 kDa ENT1 band are
most likely due to glycosylation states of the transporter, as samples treated with
deglycosidases tend to result in a sharper band. Clones of PK15-hENTl-G445L separated
by SDS-PAGE were not visible by immunoblot probed with primary FLAG Ab (Figure
4.18B). Sequences of these clones were confirmed by RNA extraction, meaning that the
absence of PK15-hENTl-G445L mutant protein is not a result o f the lack of mRNA
transcript. Due to the fact that PK15-hENTl-G445L did not bind NBMPR and was not
visible by immunoblot, it was no longer used in the assessment of hENTl
oligomerization.
More detailed functional characterization o f PK15-hENTl-G163L (Figure 4.19)
showed that the mutant had a significantly weaker affinity (IQ= 1.2 ± 0.2 nM) for
[3H]NBMPR binding than wild-type hENTl (K<j= 0.19 ± 0.04 nM) (P^0.05) (Table 4.6).
There was also a significant difference in the number of ENT 1-specific binding sites
(G163L Bmax= 19 ± 2 x 103 sites/cell; w.t. hENTl Bmax= 574 ± 60 x 103 sites/cell)
(P<0.05) (Table 4.6). There was, however, no mediated uptake of [3H]2-chloroadenosine
by PK15-hENTl-G163L (Figure 4.20). The assay was performed by incubating cells
with radiolabeled substrate for 5 seconds, a time pre-determined to most accurately
measure the linear initial rate of [3H]2-chloroadenosine uptake into transfected PK-15
cells. A subsequent measure of [3H]2-chloroadenosine uptake by PK15-hENTl-G163L

Figure 4.18 Initial [3H]NBMPR binding and Western blot screen of (A) PK15hENTl-G163L clones and (B) PK15-hENTl-G445L clones
[ HJNBMPR binding was assessed by incubating cell suspensions with increasing
concentrations of [ HJNBMPR in the presence (nonspecific binding) or absence (total
binding) of 10 pM NBTGR. Nonlinear regression analysis was used to fit hyperbolic
curves to the site-specific binding of [ HJNBMPR plotted against the free concentration
of [3H]NBMPR at equilibrium. Specific binding was determined as total binding minus
nonspecific binding. For Western blots, 50 pg protein samples o f PK-15 NTD
(Nucleoside Transport Deficient), wt hENTl, PK15-hENTl-G163L clones and PK15hENTl-G445L clones were loaded and resolved on 12.5% acrylamide SDS gels. After
transfer to PVDF membranes, immunblots were probed with primary FLAG Ab, stripped
and re-probed with primary GAPDH Ab as a loading control.
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Figure 4.19 [3H]NBMPR binding of wild-type hENTl and PK15-hENTl-G163L
cells
[3H]NBMPR binding was assessed by incubating cell suspensions with increasing
o'

concentrations of [ H]NBMPR in the presence (nonspecific binding) or absence (total
binding) of 10 pM NBTGR. Nonlinear regression analysis was used to fit hyperbolic
curves to the site-specific binding o f [3H]NBMPR plotted against the free concentration
o

of [ HJNBMPR at equilibrium. Specific binding was determined as total binding minus
nonspecific binding. Each point represents the mean ± SEM from seven independent
experiments performed in duplicate. Due to the low expression o f the mutant, an
expanded view of the PK15-hENTl-G163L and PK-15 NTD data is additionally
presented.
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Figure 4.20 Concentration-dependent uptake of [3H]2-chloroadenosine by wild-type
hENTl and PK15-hENTl-G163L cells
The initial rate of transporter-mediated uptake of [3H]2-chloroadenosine estimated using
a 5 second incubation was plotted against increasing concentrations o f [ H]2chloroadenosine. Transporter-mediated uptake (pmol/pl/s) was defined as the total uptake
minus non-mediated uptake. Non-mediated uptake was measured in the presence o f 10
pM NBMPR + 1 0 pM dipyridamole. Each point represents the mean ± SEM from three
independent experiments.
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Figure 4.21 Time course of [3H]2-chloroadenosine uptake by wild-type hENTl and
PK15-hENT 1-tel 63L cells
The mediated uptake of [3H]2-chloroadenosine was plotted against increasing times of
incubation (3-60 seconds). Transporter-mediated uptake (pmol/pl/s) was defined as the
total uptake minus non-mediated uptake. Non-mediated uptake was measured in the
presence of 10 pM NBMPR + 1 0 pM dipyridamole. Each point represents the mean ±
SEM from three independent experiments.
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Parameters

Wt hENTl

PK15-hENTl-G163L

IQ (nM )

0.19 ±0.04

1.2 ±0.2*

574 ± 60 x 103

19 ± 2 x 103*

40 ± 1 0

No uptake

8.2 ± 1.7

No uptake

Maximum Uptake (pmol/pl)

11 ± 1

No uptake

Initial Rate (Vi) (pmol/pl«s)

1.9 ±0.5

No uptake

Bmax

(sites/cell)

Km (pM)
Vrnax

(pmol/pl/s)

* Significantly different from the corresponding value for wt hENTl (P<0.05, Students ttest)

Table 4.6 Analysis of [3H]NBMPR binding and [3H]2-chloroadenosine uptake by
PK15-hENTl -G163L cells
Parameters of [3H]NBMPR binding (Figure 4.17), [3H]2-chloroadenosine uptake (Figure
'i

4.18) and the time course of [ H] 2-chloroadenosine uptake (Figure 4.19) were
determined from fitting hyperbolic curves to the specific [ HJNBMPR binding or the
specific [ H]2-chloroadenosine uptake data of each experiment. IQ and Bmax values of
binding are the mean± SEM of seven individual experiments performed in duplicate. Km
and Vmax values are the mean ± SEM o f three independent experiments. The maximum
uptake and initial rate determined from the time course of [ H]2-chloroadenosine uptake
are the mean ± SEM o f three independent experiments.
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cells over a time period of 60 seconds (Figure 4.21) confirmed that PK15-hENTl-G163L
was functionally incapable of substrate uptake.

4.2.3 Blue Native Electrophoresis of the GxxxG Mutant: PK15-hENTl-G163L
The PK15-hENTl-G163L mutant was then assessed with BNE to determine if
mutation o f the GxxxG residue affected the native molecular mass of hENTl. Isolated
membranes prepared from wild-type hENTl and PK15-hENTl-G163L cells were
solubilized with 1.0% DM, incubated for 15 min and processed under the same
conditions as previously described. Samples were resuspended in Coomassie Blue G250
sample buffer and run on native gradient gels and immunoblots were probed with primary
Anti-FLAG Ab (Figure 4.22A). Due to the lower expression levels of PK15-hENTlG163L in comparison to wild-type hENTl, 20 pg of PK15-hENTl-G163L protein was
loaded as opposed to 10 pg, in order to provide a better signal. The native molecular
weight o f PK15-hENTl-G163L when analyzed with BNE was not different from wildtype hENTl. Based on calibration against the NativeMark unstained protein ladder
(Figure 4.22C), both the mutant and wild-type hENTl protein were 162 kDa when
stained against primary FLAG Ab (Figure 4.22A) and primary ENT1 Ab (Figure 4.22B).

4.2.4 Sodium Carbonate Isolation and Blue Native Electrophoresis
The molecular weight of hENTl observed under native conditions may be due to
interactions with other proteins and not necessarily an ENT oligomer. To address this
possibility, sodium carbonate extraction was employed as a treatment that strips
associated proteins by virtue of its alkaline pH. Samples were prepared for BNE in the

Figure 4.22 Blue Native Electrophoresis of wt hENTl and PK15-hENTl-G163L;
Immunoblot probed with (A) primary FLAG Ab (B) primary SLC29A1 Ab (C)
Calibration curve of NativeMark Unstained Protein Ladder
An aliquot of isolated PK-15 NTD (Nucleoside Transport deficient), wt hENTl and
PK15-hENTl-G163L membranes was solubilized in 1.0% n-Dodecyl P-D-maltoside
detergent and resuspended in Coomassie Blue G250 sample buffer. Samples o f 10 pg
were run on a 4-16% Native BisTris gradient gel. Due to the lower protein expression of
PK15-hENTl-G163L, 20 pg of the mutant was loaded to produce a suitable signal. After
transfer, immunoblots were probed with primary Anti- FLAG Ab, stripped and re-probed
with primary ENT1 Ab. The image shown is a representative blot o f n=3. R f values
determined from the NativeMark Unstained Protein Ladder were used to generate a
calibration curve of Molecular Weight plotted against R f value, in order to predict the
molecular weight o f bands o f interest.
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same manner already described, with the exception that cell suspensions were incubated
with 100 mM sodium carbonate for 1 hour and centrifuged at 100, 000 x g for 1 hour at
4°C during the preparation o f membranes. On native gels, the sodium carbonate treated
wild-type hENTl and PK15-hENTl-G163L samples did not run differently from control
samples on BNE (Figure 4.23A) when stained for both FLAG-tagged protein (Figure
4.23 A) and ENT1 protein (Figure 4.23B). The molecular weight of all samples based on
the unstained protein ladder calibration curve was 162 kDa (Figure 4.23C).

Figure 4.23 Blue Native Electrophoresis of Sodium Carbonate Isolated wt hENTl
and PK15-hENTl-G163L Samples; Immunoblot probed with (A) primary FLAG
Ab (B) primary SLC29A1 Ab (C) Calibration curve of NativeMark Unstained
Protein Ladder
Aliquots of isolated PK-15 NTD (Nucleoside Transport deficient), wt hENTl and PK15hENTl-G163L membranes were either prepared as usual or extracted with 100 mM
sodium carbonate. Samples were then solubilized in 1.0% n-Dodecyl P-D-maltoside
detergent and resuspended in Coomassie Blue G250 sample buffer. Samples o f 10 pg
were run on a 4-16% Native BisTris gradient gel. Due to the lower protein expression of
PK15-hENTl-G163L, 20 pg o f the mutant was loaded to produce a suitable signal. After
transfer, immunoblots were probed with both primary Anti- FLAG Ab and primary
ENT1 Ab. The image shown is a representative blot o f n=3. R f values determined from
the NativeMark Unstained Protein Ladder were used to generate a calibration curve of
Molecular Weight plotted against R f value, in order to predict the molecular weight o f
bands of interest.
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CHAPTER 5. Discussion

As is common with a number o f hydrophobic membrane proteins, the 3D
crystallographic structural conformation o f hENTl has yet to be elucidated (99). Sitedirected mutagenesis is often used as a tool to probe the functional importance of residues,
with the end goal of determining the structural requirements necessary for optimal
transport and ligand binding. A more detailed understanding o f the substrate-binding site
and translocation pathway will open the gate for applications in the clinical development
of nucleoside analog drugs. To date, a number o f residues have been identified that are
involved in inhibitor interactions with, and transport of nucleosides by ENT1 (11, 12, 58,
76, 77, 88, 89, 90). Initial studies showed that TM domains 3-6 o f ENT1 played a
significant role in the inhibitor-binding site, with minor contributions being made by TM
1 and 2 (81). However, residues identified to date are widespread, indicating that the
inhibitor and substrate-binding sites involve complex interactions from residues within
multiple TM domains. Indeed, threaded and ab initio models of nucleoside transporters
suggest that TM domains 1, 2, 4, 5, 7, 8, 10 and 11 line the permeation pathway (85).

5.1 Characterization of TM 1 and TM 2 Mutants of hENTl
This project was undertaken initially to assess the contribution o f specific residues
within the first two transmembrane domains to the functionality o f hENTl. These
residues, namely, N81, T96, G22 and C87, were chosen based on a combination of their
unique functional side chain characteristics and their proximity to previously identified
residues within the domains. The neighbouring residues W29, M33, M89 and L92 have
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all been found to make some contribution to the substrate transport capacity and/or
inhibitor interactions with hENTl (58, 90, 11, 12). The PWN motif, consisting of the
residues proline 28, tryptophan 29 and asparagine 30, was additionally found to influence
targeting o f the transporter to the plasma membrane (55). An evolutionary analysis of over
45 species o f vertebrate, invertebrate, fungal and prokaryote ENTs found that all ENTs
had four highly conserved regions, the first of which correlates to TM domain 1 (1). This
high level o f conservation suggests that the residues within this region are functionally
and structurally important. Additionally, the extracellular loop between TM 1 and 2
contains the most sequence differences amongst the species variants o f ENT 1 (24). Given
the fact that substrates and inhibitor affinities vary greatly across species, this is additional
reason to study the TM 1 and 2 region.

5.1.1 [3H]NBMPR Binding and [3H]2-chloroadenosine Uptake by wild-type hENTl
transfected PK15-NTD cells
[3H]NBMPR binding was used as a tool to assess the integrity o f the inhibitor
binding site o f the wild-type and mutant transporters. NBMPR exhibits high affinity
reversible binding, preferentially to the outward facing conformation of the es transporter.
This binding is believed to be stabilized by the interaction o f the nitrobenzyl ring of the
inhibitor with an adjacent hydrophobic domain on the transporter (35). The NBMPR
binding site density determines the number of es transporters present, but due to its high
lipophilicity it is not necessarily specific to those at the plasma membrane. This is of
importance because some cells contain a cytoplasmic pool o f es transporters that act as a
regulatory reserve to cycle to the membrane when needed (83, 54). The rate of [3H]2-
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chloroadenosine uptake was measured in order to assess the differential capacity of wildtype hENTl and the mutants for substrate transport. The stability o f 2-chloroadenosine
makes this adenosine derivative a useful alternative, as it undergoes little intracellular
metabolism. This provides a more accurate measurement o f transport kinetics (33, 78).
As mentioned in the results section, any differences observed in the number of
ENT 1-specific binding sites inferred from the

B max

of [3H]NBMPR binding are not

necessarily a product o f the point mutation affecting protein processing and expression.
More likely, they are a result of the transfection efficiency associated with using a
recombinant overexpression model. Typically this problem is overcome by presenting the
data as a

B max/V m ax

ratio that considers the functional capacity o f a cell line, while taking

into account the number o f transporters that are present. However, with the data presented
in this thesis, the

B max

observed in membrane preparations does not necessarily appear to

be reflective o f the Bmax values observed in whole cells. A very clear example of this is
with the mutant PK15-hENTl-N81A, where there is a large decrease in the ENT1specific binding o f isolated membranes compared to whole cell PK15-hENTl-N81A data
that is not mimicked in wild-type hENTl cells/membranes.
It should be noted that crude membrane preparations, in addition to plasma
membranes, also contain some intracellular membranes such as those from the
Endoplasmic Reticulum (ER). However, given the fact that a portion of intracellular
transporters are removed through the process o f isolating membranes, the number of
transporters quantified in membrane preparations is still more representative of those that
are contributing to the functional uptake of ENT 1 at the plasma membrane. In order to
make an appropriate interpretation of the results, the ratio o f the whole cell wild-type vs.
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mutant Bmax values, as well as a ratio of the membrane wild-type vs. mutant Bmax values
is presented. This gives an indication of the number o f transporters expressed in a mutant
cell line relative to its paired wild-type data, and then an idea o f whether that relative
difference changes between whole cells and preparations of isolated membranes. This
will then be related to the rate of uptake observed to see whether any changes in
functional transport are an effect of the mutation, or because there are different numbers
o f transporters present in the wild-type hENTl and mutant cell lines due to transfection
efficiency. An interpretation o f such data obtained with each mutant will be discussed in
the respective sections to follow.
In terms o f interpreting curves fit to the inhibition of [ HJNBMPR binding data,
the raw data gained provides IC 50 values that are then used to determine the Kj values of
the inhibitors. The IC 50 is the concentration of an inhibitor that produces a 50% inhibition
of specific binding. Inhibitor affinities, known as Ki values, are then calculated using the
equation o f Cheng-Prusoff, taking into consideration the varying affinities that different
transporter variants have for NBMPR and the concentration of NBMPR used. In this
thesis only the Kj values are reported, because IC 50 values do not take into account the
differences in affinity for NBMPR of wild-type and mutant transporters. Ki values are
tailored to situations where the Hill slope (nH) is equal to 1. As noted in the results
section, inhibition curves o f the PK15-hENTl-N81A membranes have an nH o f less than
1 for several o f the inhibitors; thus, in these cases the Ki values calculated should be
considered estimates only and are shown for comparative purposes.
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5.1.2 PK15-hENTl-N81A
The PK15-hENTl-N81A mutant had an approximate 3-fold lower affinity for the
ENT 1-selective inhibitor NBMPR than the wild-type transporter. This prompted the
further characterization o f PK15-hENTl-N81A for any changes in sensitivity of the
mutant to other known inhibitors of hENTl. The abilities o f dipyridamole, draflazine and
dilazep to competitively inhibit [3H]NBMPR binding to wild-type hENTl and PK15hENTl-N81A were assessed in both whole cell and isolated membrane preparations. No
changes were seen in the capacity of dipyridamole to inhibit [ H]NBMPR binding to
PK15-hENTl-N81A. There were, however, slight changes in the affinities of the mutant
to the other two inhibitors. Both whole cell and membrane preparations of PK15-hENTlN81A had an approximate 3 to 4-fold reduced sensitivity to draflazine. There was also an
approximate 6-fold reduction in sensitivity to the inhibitor dilazep, though this change
was only significant in PK15-hENTl-N81A membranes. In terms of the substrate 2chloroadenosine, residue N81 does not appear to contribute to the substrate-binding site of
hENTl, as there was no difference in the affinity of [3H]2-chloroadenosine uptake by
PK15-hENTl-N81A compared to wild-type hENTl.
These findings suggest that the N81 residue plays a role in the interactions of
inhibitors with hENTl. Neighbouring residues based on the helical wheel projection of
TM 2 (Figure 2.IB) have already been implicated in the binding of inhibitors to the
transporter. NBMPR was only able to inhibit 0-20% o f adenosine transport by L92
mutants, compared to the 82% inhibition of uptake observed with wild-type transporters
(11). A reduced sensitivity to the inhibition of adenosine transport by dilazep was also
observed for these mutants (11). Mutations of the residue M89 likewise affected
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interactions o f NBMPR with the transporter, and these effects were synergistically
enhanced by co-mutation o f the residue SI 60 in TM 4 (12). The mutation o f an asparagine
residue to an alanine removes the amide group, which consists of carbonyl group (C=0)
linked to a nitrogen atom. Asparagines are polar residues that can participate in hydrogen
bonding to solvent, the peptide backbone or to polar compounds in the binding sites of
proteins. It is reasonable to consider that the replacement o f N81 with an alanine disrupts
a hydrogen bond, either directly with a polar moiety on the inhibitors or with a
surrounding residue that influences the affinity o f inhibitor binding. The loss of hydrogen
bonding at position 81 could explain the finding that the N81A mutant displays a reduced
sensitivity to inhibitors.
The finding that residues of TM 2 have a reduced sensitivity to inhibition by
NBMPR is not surprising because these studies have also found that these residues affect
purine-selective transport (11, 12). NBMPR is a purine nucleoside analog, so the inhibitor
and substrate-binding sites share an overlapping specificity for the purine ring of these
compounds. The residues clustered together on this face o f the TM 2 helical wheel
projection (Figure 2 .IB) appear to contribute to that interaction. While NBMPR is a
nucleoside analog, draflazine and dilazep are structurally unrelated chemical compounds.
Draflazine is a chemical derivative of the compound lidoflazine, belonging to the class of
piperazine Ca

channel blockers, and dilazep is an alkyldiamine aromatic ester (56).

Structurally these inhibitor compounds are unrelated to one another, so while there is an
overlap, each inhibitor appears to have uniquely individual interactions with the
transporter. It is clear that there is a complex interplay between the residues L92, M89 and
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N81 o f TM 2, along with other residues throughout the transporter, that jointly contribute
to the binding o f inhibitors to hE N T l.
There is a clear difference with the whole cell and membrane data of the PK15hENTl-N81A mutant in the following areas: there is a large drop in the Bmax of
[3H]NBMPR binding to PK15-hENTl-N81A membranes, relative to intact cells, that is
not seen in wild-type hEN Tl; there is a deviation from a Hill slope of -1 for inhibition
profiles o f PK15-hENTl-N81A membranes that is not seen in either PK15-hENTl-N81A
cells or any wild-type hENTl cells and membranes; there is a reduced sensitivity to the
inhibitor Dilazep in PK15-hENTl-N81A membranes that is not seen in PK15-hENTlN81A cells.
The reason for this disparity between whole cell and membrane data is somewhat
unclear. Immunofluorescence (IF) was attempted in an effort to address the cellular
location o f the ENT1 protein. IF analysis of FLAG-tagged wild-type hENTl cells show a
large intracellular pool of hENTl protein that is not present at the membrane. No
fluorescence was observed in PK15-NTD cells that served as a negative control.
Unfortunately the protein was widely distributed throughout the cell and it was not
possible to define the plasma membrane specific component o f ENT1 in this PK15 cell
line. Further studies with IF were discontinued for this reason.
Immunocytochemistry o f PK15-hENTl-N81A cells was not performed, but the
presence o f an intracellular population of transporters explains the large drop in the
number o f ENTl-specific binding sites when PK15-hENTl-N81A membranes are
prepared from whole cells. The calculated ratio o f w.t. Bmax/N81A Bmax in whole cells is
0.8 ± 0.2. In isolated membranes the ratio of w.t. Bmax/N81A Bmax changes significantly to
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3.7 ± 0.1 (P<0.05). These ratios mean that there are fewer transporters in wild-type
hENTl whole cells compared to PK15-hENTl-N81A but through the process of
preparaing isolated membranes, a large number o f PK15-hENTl-N81A transporters was
lost and the wild-type hENTl preparation now had 3.7 times more transporters relative to
the PK15-hENTl-N81A preparation. These ratios are a further confirmation of the
presence o f a large intracellular pool of ENT1 in PK15-hENTl-N81A that is removed by
the preparation o f crude membranes. In terms of relating these ratios to functional
capacity, while there is a significant difference in the rate o f substrate uptake in N81A
cells compared to wild-type hENTl (w.t.

V max=

10.2 ± 2.7 pmol/pl/s; N81A

V max=

6.1 ±

0.3 pmol/jal/s, P<0.05), this equates to the wild-type hENTl rate o f uptake being
approximately 1.7 times greater than that of PK15-hENTl-N81A cells. This does not
match the fact that there are 3.7 times more wild-type hENTl transporters than PK15hENTl-N81A transporters potentially contributing to functional uptake at the membrane.
Therefore, although there is less ENT1 protein available to partake in substrate transport,
the N81A mutant transporters still have a slightly better capacity for substrate uptake than
does wild-type hENTl.
Hill slopes for the competitive inhibition profiles o f PK15-hENTl-N81A and
wild-type hENTl in all cases was equal to -1, except for the inhibitor profiles of PK15hENTl-N81A membranes. A hill slope of less than one generally implies the existence of
a heterogeneous receptor population, each with different affinities. Or it is possible that
the hill slope is because of negative cooperativity, that is, the idea that the binding of a
ligand decreases the affinity o f remaining, non-liganded binding sites. It is difficult to
propose either o f these theories based on the differences observed between the membrane
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and whole cell data o f competitive inhibition profiles. If multiple receptor populations
were present or inhibitors were binding in a negatively cooperative manner, the deviation
from a hill slope o f 1 would also be seen in whole cell competitive inhibition profiles. It is
more likely that the procedure for the preparation o f crude membranes in some way
affected the integrity o f the PK15-hENTl-N81A samples. Though the reason for this
difference is unclear, perhaps a modulating protein that masks the cooperative activity of
these mutant transporters in intact cells is being lost during the preparation of membranes,
or perhaps the loss o f endogenous nucleosides when cells are processed to membranes is
affecting the state o f the transporter.
With respect to the differential changes in sensitivity to dilazep observed in PK15hENTl-N81A cells and membranes, there is a possibility that the intracellular pool of
hENTl may be accessible to membrane permeable NBMPR and inaccessible to watersoluble dilazep. This would explain the changes in K* o f dilazep seen at the membrane,
but not in whole cells. However, this is unlikely because it suggests that dilazep would be
unable to fully displace NBMPR in competitive binding experiments, and complete
inhibition o f NBMPR was observed in both whole cell and membrane preparations. More
likely these results are, again, an artifact o f the membrane isolation procedure relating to
the purity o f the samples.

5.1.3 PK15-hENTl-T96A
The residue threonine 96 does not appear to play a role in the interaction of
NBMPR with the transporter; the mutant PK15-hENTl-T96A had an affinity for
[3H]NBMPR binding that does not differ from that o f wild-type hENTl. Interestingly
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though, PK15-hENTl-T96A displayed a significantly higher Km, that is, a weaker affinity
-j

___

for the uptake o f the purine nucleoside derivative, [ H]2-chloroadenosine. The
substitution o f an alanine in the place of a threonine essentially removes the hydroxyl
group and one carbon atom from the functional side chain o f the threonine residue. It is a
possibility that the hydroxyl group o f the T96 provides a contact, whether directly to the
substrate or via neighbouring residues, that facilitates higher affinity binding of the
substrate 2-chloroadenosine.
This finding suggests that the residue T96 is in some way implicated in the
substrate-binding site o f hENTl, either directly within the substrate translocation
pathway or as part o f an indirect interaction or conformational change that promotes
substrate binding. Given the fact that PK15-hENTl-T96A does not display a very large
fold-change in affinity, it is more likely that T96 plays some secondary contributing role
to mediate substrate transport. Surrounding residues that lie near T96 on the helical wheel
projection o f TM 2 (Figure 2. IB) have also been found to affect the transport of purine
nucleosides. Mutations o f M89 increase the Km of adenosine and guanosine transport
(12), while L92 is selective for transport of the purine nucleosides, inosine and guanosine
(11). It appears that these grouped residues o f TM 2 play an important role in the purineselective component of hENTl substrate transport. These findings correlate with the ab
initio model o f the nucleoside transporter, which proposes that TM 2 lines the permeant
translocation pathway (85).
In terms o f the relationship between transporter expression and functional
capacity o f PK15-hENTl-T96A with respect to wild-type hEN Tl, the ratio of w.t.
Bmax/T96A Bmax in whole cells was 2.9 ± 0.2 and the ratio o f w.t. Bmax/T96A Bmax in
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membranes significantly changed to 1.6 ± 0.1 (P<0.05). These numbers are significantly
different because although there are consistently more wild-type hENTl transporters
present in both whole cells and membranes than T96A, a greater number of wild-type
hENTl transporters is lost during the preparation o f membranes. So there are 1.6 times
more wild-type hENTl than PK15-hENTl-T96A mutant transporters available that
potentially contribute to substrate transport, but the rate o f uptake in wild-type hENTl
and PK15-hENTl-T96A cells is not significantly different (w.t.
pmol/pl/s; N81A

V max-

V max=

3.5 ± 0.2

3.1 ± 0.5 pmol/pl/s, P>0.05). Therefore, mutant PK15-hENTl-

T96A transporters possess a more efficient rate of uptake than does wild-type hENTl.
This is o f interest considering the fact that the PK15-hENTl-T96A mutant has a lower
affinity for the uptake o f 2-chloroadenosine.

5.1.4 PK15-hENT 1-G22A
A basic characterization of the PK15-hENTl-G22A mutant was undertaken prior
to its loss o f expression, as mentioned in the results. Unfortunately the mutation was not
stable and since the other clones for which sequences were confirmed by RNA extraction
did not have measurable levels o f es transport detectable by NBMPR binding, this
prevented any further investigation of this mutant. There were, however, some interesting
initial findings and because o f this, the PK15-hENTl-G22A plasmid is currently being re
transfected in order to further characterize the effects o f this mutation. PK15-hENT 1G22A had a significantly lower affinity for [3H]NBMPR binding than wild-type hENTl
does. Although the PK15-hENTl-G22A mutant had a very low number o f ENT1 binding
sites per cell, this measurable level of binding is above the baseline of non-transfected
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PK-15 NTD cells. There was no change in the affinity o f PK15-hENTl-G22A in terms of
[ H]2-chloroadenosine uptake. These findings suggest that the residue G22 is involved in
the inhibitor-binding site with respect to NBMPR, but is not contributing to the substrate
binding site.
The helical wheel projection of TM 1 (Figure 2.1 A) places G22 in the immediate
vicinity o f the previously characterized W29 and M33 residues o f hENTl. Mutations of
W29 have been found to affect interactions with a range o f inhibitors, namely,
dipyridamole, dilazep, soluflazine and NBMPR (58). The M33 residue also interacts with
dipyridamole, dilazep and to a slightly lesser extent, soluflazine (90). It is clear that this
region o f TM 1 makes an important contribution to the inhibitor-binding site of hENTl.
Each residue is influential to different combinations o f inhibitors, going along with the
theme that inhibitors have distinct interactions within the binding site. For any future
work with a newly transfected PK15-hENTl-G22A mutant, it will be o f interest to see if
this change in sensitivity to NBMPR of the PK15-hENTl-G22A extends to any other
ENT1 inhibitors, although direct speculation on the subject cannot be made at this point.
Glycine residues are generally inserted into transmembrane domains as a
positional necessity to provide flexibility. Consistent with this concept, in the helical
wheel projection o f TM 1 residue G22 is surrounded by a number of tryptophan and
phenylalanine residues with bulky aromatic side chains (Figure 2.1 A). The mutation of a
glycine to an alanine residue introduces a slightly bulky methyl side chain into a closely
fitted area that may be without room for substitution. Though the change is not a drastic
one, the alanine mutation may introduce steric bulk that does not entirely abolish, but
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lessens the interactions o f surrounding residues necessary for the normal higher affinity
binding of NBMPR.
W29 was additionally identified in another study of the PWN (Proline28,
Tyrptophan 29, Asparagine 30) motif of TM domain 1 o f hENTl. Mutations of P28, W29
and N30 prevented plasma membrane localization and these mutant transporters were
retained in the ER (55). Being adjacent to W29 on the helical wheel projection of TM 1,
perhaps the difficulty in producing a stably transfected mutant with measurable levels of
transporters is hindered by the association of the G22 residue with this PWN m otif
Perhaps the mutation was not stable in the sense that transporters were retained in the ER
or degraded. In an evolutionary analysis performed by Acimovic and Coe 2002 of over 45
ENT sequences from different species, a highly conserved sequence o f residues was
identified

in

the

region

corresponding

to

TM

1

of

hENTl,

namely

GXGS/TXXPW/YNXXX, where X is usually a hydrophobic residue (1). This conserved
region contains G22 as well as the previously identified PWN m otif and M33 of hENTl.
The specific glycine residue at position 22 in hENTl was conserved across 39 species of
ENTs (1). This high level o f conservation coupled with the prior identification of residues
P28, W29, N30 and M33 suggests that this region, including G22, is functionally
important to ENTs.
Other previously characterized glycine residues in hENTl have been noted to be
sensitive to point mutation changes. Mutations o f glycine 179 in TM 5 of hENTl resulted
in little to no transporter activity, with more conservative mutations to alanine and serine
residues being more easily tolerated (76). G179A was the only mutant with low, but
measurable [3H]uridine uptake and the residue was found to interact with NBMPR.
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Glycine 184 mutants were not functional and the residue was implicated in plasma
membrane targeting (76). Mutation o f glycines 392 and 396 in TM 11 o f PfENTl were
also not well tolerated. They abolished adenosine transport and caused a significant
reduction in protein expression (67). These glycine residues are highly conserved across
ENT homologues (Figure 2.4B) and are equivalent to glycines 441 and 445 o f the GxxxG
m otif in TM 11 o f hENTl (67). The functional capacity o f the PK15-hENTl-G22A
mutant compared to the number o f transporters present cannot be accurately described due
to the lack o f membrane data. However, there are a much lower number o f ENT 1-specific
binding sites in whole cells o f PK15-hENTl-G22A compared to wild-type hENTl, as
well as a much lower rate of 2-chloroadenosine uptake. It is reasonable to suggest that the
low amount of observable substrate uptake is due to the low amount of PK15-hENTlG22A protein expressed in the cell line.

5.1.5 PK15-hENTl-C87S
Mutation o f the cysteine 87 residue to serine did not have a drastic effect on the
characterization o f transporter kinetics when compared to wild-type hENTl. There was
no change in the affinity o f PK15-hENTl-C87S to [3H]NBMPR binding, indicating that
this residue does not play a role in the interaction of NBMPR with hENTl. There was a
very slight, but significant increase in the affinity for [3H]2-chloroadenosine uptake.
Considering the fact that PK15-hENTl-C87 is positioned on the opposite side of the TM
2 helical wheel projection (Figure 2.IB) as N81, M89, L92 and T96, it is not surprising
that C87 does not make significant contributions to the inhibitor and/or substrate-binding
site.

128
The higher affinity of [ H]2-chloroadenosine uptake exhibited by the PK15hENTl-C87S mutant was very slight. More likely this was an indirect result of the
mutation change rather than an indication that C87 is directly involved in the substrate
binding site. Cysteine residues are a relative rarity in proteins. They mainly have a
tendency to be found within enzyme catalytic sites or to provide stability of the folded
protein via disulfide-linked cystines. These residues do have the capacity to participate in
intrahelical hydrogen bonding in a-helical domains of proteins (20). The sulfhydryl of
the cysteine residue hydrogen bonds to a carbonyl oxygen in the preceding turn of the a
helix. The tendency for cysteines to form intrahelical hydrogen bonds does not appear to
depend on the whether the protein is buried or solvent-accesible, but whether the cysteine
residue is free or disulfide linked. Cystines that are disulfide linked do not tend to
additionally form hydrogen bonds (20). The hydroxyl group of serine is more polar than
the sulfhydryl group o f cysteine so the mutation o f a cysteine to a serine residue produces
slightly more favourable hydrogen bonding. This appears to be an interaction with
position 87 o f hENTl and the surrounding environment that produces k slightly higher
affinity substrate transport.
The ratio o f w.t. Bmax/C87S Bmax in whole cells was 2.9 ±0.1 and the ratio of w.t.
Bmax/C87S Bmax in membranes was 2.1 ± 0.1. There are a consistently greater number of
wild-type transporters being expressed compared to the PK15-hENTl-C87S mutant,
regardless o f the preparation under consideration. The rate o f 2-chloroadenosine uptake
by wild-type hENTl in whole cells was not significantly different from PK15-hENTlC87S (w.t. Vmax= 6.5 ± 0.7 pmol/pl/s; N81A Vmax= 6.4 ± 0.4 pmol/pl/s, P>0.05).
Although there are 2.1 times more wild-type hENTl

than PK15-hENTl-C87S
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transporters potentially contributing to substrate uptake, both the wild-type and the
mutant have the same rate of uptake, meaning that approximately half the number of
mutant PK15-hENTl-C87S transporters are necessary to provide substrate uptake
capacity as wild-type hENTl.

5.2 Oligomerization of hENTl
In addition to targeting the functional significance o f certain residues within the
first two TM domains o f the transporter, this thesis additionally investigated the potential
oligomerization o f hENTl. Though a number of proteins are now known to form
oligomeric species, including GPCRs and other membrane transporters (82), this
phenomenon has not yet been reported in nucleoside transporters. ENTs are traditionally
classified as monomers, with a molecular weight o f approximately 45 to 64 kDa,
depending on the glycosylation state o f the transporter and the species in which it is found
(21). A number o f photoaffinity labeling, SDS-PAGE and immunoblotting studies,
including those performed in our lab, have noted higher molecular weight bands of ENTI
that were suggestive of oligomeric forms of the transporter (42, 19, 86, 53). The concern
with interpreting these results is that undesirable higher bands observed with these
denaturing techniques are typically attributed to protein aggregation from improper
sample preparation. A more deliberate method is needed in order to properly assess the
oligomerization potential o f ENTI proteins. In this thesis, the native higher order
molecular weight o f hENTl was determined as a starting point to see whether or not
hENTl has the potential to interact as an oligomer.
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5.2.1 Blue Native Electrophoresis (BNE)
Blue native electrophoresis (BNE) is a technique that is designed to isolate and
analyze membrane proteins in a native manner (94, 65). The distinctive feature of BNE is
the use o f Coomassie blue G-250, an anionic dye that induces a negative charge shift on
proteins, allowing migration during electrophoresis without the use of harsh ionic
detergents. Instead, nonionic detergents are used to ensure solubilization conditions that
are mild enough to maintain native protein complex association. Additionally, the
negative charge induced by Coomassie blue G-250 prevents protein aggregation (65). In
this way, individual proteins are separated by size, based on their relative mobility
through an acrylamide gradient gel.
BNE is a fairly straightforward technique for the separation o f all membrane
proteins, but the choice of detergent and solubilization conditions need to be tailored to
the protein o f interest to ensure successful separation. Preliminary experiments concerning
the native separation of hENTl were conducted with the nonionic detergent Triton X-100
(TX-100). This was chosen because it is one of the most commonly used detergents for
the BNE technique (66) and was readily available in the lab. The other detergents
typically used are digitonin and dodecylmaltoside (DM). When solubilized with a TX-100
concentration o f 1.0% (w/v) for 15 minutes, wild-type hENTl membranes were visualized
by immunoblot at a molecular weight o f approximately 147 kDa. This is approximately
three times the predicted molecular weight of 55 kDa for the hENTl monomer.
Though initial experiments were performed with TX-100, previous studies in our
lab with the functional reconstitution of ENT1 (27) urged the replacement of this
detergent with dodecylmaltoside (DM) as the nonionic detergent of choice. In this
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previous study, compounds with maltoside structures most efficiently solubilized
nucleoside transporters. Those with longer alkyl chains, such as dodecylmaltoside,
solubilized better but also had higher critical micelle concentrations (CMC), which was
unsuitable for the reconstitution portion of the study. As a result, decylmaltoside, which
has a shorter alkyl chain, was chosen for further analysis with reconstitution studies. It
was found to most efficiently solubilize nucleoside transporters, while retaining optimal
[3H] NBMPR binding and mediated uptake capacity when compared to a range of other
non-maltoside

detergents.

In terms

of solubilization, maltoside

detergents

like

dodecylmaltoside were found to best mimic the native lipid environment, thus
maintaining the integrity o f ENT1 functionality (27). Based on these findings,
dodecylmaltoside was chosen as the best option for the solubilization o f hENTl.
Dodecylmaltoside (DM) is commonly used for BNE and suitable detergent
concentrations that have been documented in the literature range from 0.2% to 2.0% (w/v)
(64, 65, 66, 94). Based on a preliminary test (refer to Appendix Figure 2), 0.2% was
chosen to provide accurate solubilization without the protein denaturation typical of
higher detergent concentrations. The native separation of wild-type hENTl membranes
solubilized with 0.2% (w/v) DM yielded hENTl with a molecular weight of
approximately 127 kDa. Based on the protein being targeted, reports in the literature have
noted anywhere from 15 to 45 minutes of sample incubation with detergent to ensure
solubilization (66). The 127 kDa hENTl band was observed at both a 15 and 30 minute
incubation o f wild-type hENTl membrane samples with DM, indicating that a shorter
time point is sufficient for hENTl protein separation. Compared to the 147 kDa band
observed with TX-100 solubilization, this finding o f 127 kDa falls within the 20% error
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rate associated with molecular weight estimation using a native ladder calibration curve.
The molecular weight o f a protein observed can also vary slightly based on the detergent
being used (94), which may also contribute to the slight discrepancy observed between the
molecular weight o f wild-type hENTl when solubilized with TX-100 and DM.
In addition to characterizing N81 of TM 2 for its contribution to inhibitor binding
and substrate transport, this residue was also investigated for any involvement in the
native molecular weight o f hENTl. N81 is one of two asparagines in an Asn pair, a motif
known to aid helical association (45). As such, the potential o f the mutant N81A to affect
the higher molecular weight band observed with BNE for hENTl was an issue of interest
that was addressed. No visible change in the molecular weight between wild-type hENTl
and N81A was observed. Therefore the residue N81 does not contribute to hENTl
oligomerization or intraprotein helix organization critical for protein function. Consistent
with the [3H] NBMPR binding data, relative amounts o f wild-type hENTl and N81A
protein visible on the immunoblot corroborate changes seen in ENT 1-specific binding
sites between wild-type hENT 1 and N 81A.
Under native non-reducing conditions, the protein complex that contains hENTl
based on immunoblotting has a molecular weight of approximately 127-147 kDa,
depending on the detergent used. To date, there is no published literature on the
oligomerization o f nucleoside transporters. There has been speculation as to the existence
of oligomerization in a few instances. Immunoblots of rat liver crude membranes
observed a strong band at approximately 60 kDa, the glycosylated weight of rat ENT1, as
well as numerous higher molecular weight bands that ‘probably represent oligomers of the
transporters’ (42). Sharp bands just below 50 kDa and at 100 kDa were visualized when
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Western blots o f rat dorsal horn and rat dorsal root ganglion homogenate were probed for
rat ENT1. The authors speculated that the heavier band might be a dimeric form of ENT 1
(19). Immunoblots o f rat heart tissues probed for rat ENT1 showed a band at
approximately 60 kDa, as well as higher bands attributed to possible oligomerization (53).
A study that characterized recombinant hENTl expressed in Saccharomyces cerevisiae
performed immunoblots o f hENTl membranes and observed bands at 40, 80 and 120
kDa. The stronger 40 kDa molecular weight band represented the monomeric species of
hEN Tl, while the minor 80 and 120 kDa bands were predicted to be dimeric and trimeric
species of the transporter (86). A higher 130 kDa molecular weight band was also seen on
immunoblots from another study with membranes o f hENTl expressed in Saccharomyces
cerevisiae. Though the authors chose not to present this data in their paper, they
speculated that this higher molecular weight band was most likely a dimer of hENTl (76).
The higher molecular weight species observed in these studies under the denaturing
conditions o f SDS-PAGE were unexpected findings. In contrast, this thesis presents the
first intentionally reported investigation of ENT higher order oligomerization in a native
system.

5.2.2 Functional characterization of the GxxxG Mutants: PK15-hENTl-G163L and
PK15-hENT X-G445L
The GxxxG m otif has been implicated in the oligomerization of a number of
proteins (75). The glycine residues of the GxxxG m otif provide a flat interface, allowing
the side chains o f neighbouring residues to form strong Van der Waals interactions that
facilitate helical associations. An important feature of the m otif is the presence of large P-
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branched side chains surrounding the glycine residues that act to promote stability. A
combination o f large residues such as valine, leucine and isoleucine and small residues
like glycine, alanine and serine is necessary, presumably to prevent the overcrowding of
side chain moieties (70). A library of randomized transmembrane sequences based on the
GpA GxxxG segment, 75LIxxGVxxGVxxT87, found that the majority o f sequences with a
high

affinity

for

oligomerization

were

either

G[Lg]xxG[Lg]xx[Sm]

or

5G[Sm]xxG[Sm]xxT13. The glycine residues are at positions 5 and 9. Positions 6 and 10
tend to be similar residues in terms of size, while position 13 is the opposite. [Lg] residues
typically refer to P-branched amino acids valine, leucine and isoleucine; [Sm] residues
refer to small amino acids like glycine, alanine and serine (70). It should be mentioned
that these findings do not represent all possible sequences, particularly given the fact that
the specific GpA m otif was not positively identified in the library screen for
oligomerization (70).
Proteins with identified GxxxG motifs known to contribute to oligomerization are,
of course, not identical in sequence to the GpA motif. There are variations to the motif.
Sequences can contain tandem repeats of the GxxxG m otif that increase the inherent
affinity o f the protein for oligomerization. For example the Heliobacter pylori toxin has
three consecutive GxxxG repeats (49). In some cases, the glycine residues of the tandem
repeats can be replaced with other small residues. For example, the apoptotic protein
BNIP3 contains multiple tandem repeats with a combination o f glycine, alanine and serine
residues (79). There also exist GxxxG-like motifs such as those belonging to the integrin
receptor family (74). The important features to note are the presence o f two small residues
(typically glycine) separated by three spaces, with a surrounding combination of p-
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branched

amino

acids

and compensatory smaller residues.

The

sequences in

transmembrane domains 4 and 11 of hENTl (Figure 2.4) contain these generalized key
features and are as follows: TM 4: 159GSLFGLAGL167 and TM 11: “ 'GLALGAVFS449.
The combination o f leucine, alanine and serine residues with appropriate spacing between
two glycines suggest that these are indeed GxxxG motifs potentially contributing to
oligomerization and/or helical packing. In order to assess the GxxxG motifs of TM 4 and
TM 11 in hEN Tl, the mutants PK15-hENTl-G163L and PK15-hENTl-G445L were
made, functionally characterized and subjected to BNE.
The PK15-hENTl-G163L mutant has a lower affinity for NBMPR than wildtype hENTl. Although there are much less ENT 1-specific binding sites present in
comparison to wild-type hENTl, the number of es transporters measurable by
[3H]NBMPR binding is still above baseline PK-15 NTD (nucleoside transport deficient)
cells. This may be due to transfection efficiency or the mutation might be interfering with
protein processing. All clones of PK15-hENTl-G163L displayed similarly low numbers
of es transporters, supporting the idea that the substitution o f G 163 with leucine affected
protein processing. Immunoblots o f whole cell and isolated membrane sample
preparations o f PK15-hENTl-G163L additionally confirm the presence of FLAG-tagged
hENTl protein. Interestingly, there was no observable uptake of [3H]2-chloroadenosine
even when the incubation of PK15-hENTl-G163L cells with radiolabeled substrate was
allowed for longer periods o f time, up to 60 seconds. Based on these findings, the PK15hENTl-G163L mutant is present within the cell but is functionally incapable of substrate
transport. The lack o f uptake and presence of protein does not necessarily imply that these
are non-functional transporters at the plasma membrane. Although protein is visible on
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immunoblots o f PK15-hENTl-G163L membranes, the preparation of crude membranes
by centrifugation includes not only plasma membranes, but endoplasmic reticulum (ER)
membranes as well. It is quite possible that the mutant transporter, while being made, is
stuck in the ER and is non-functional. This idea supports the observed results, especially
given the fact that [3H]NBMPR is membrane permeable. The other alternative is that the
mutation to residue G163 did not affect the targeting of the mutant transporter to the
plasma membrane, but was so critical that the functional capacity for substrate transport
was diminished. Though this seems more unlikely, this study did not distinguish between
the es transporters at the plasma membrane and those within the intracellular compartment
of the cell, making either of these explanations a possibility.
The PK15-hENTl-G445L mutant was unable to bind NBMPR and was not visible
by immunoblot when stained for FLAG-tagged protein, despite transfection of the cells
being confirmed by mRNA extraction and subsequent DNA sequencing. A recent study
o f the Plasmodium falciparum equilibrative nucleoside transporter 1 (PfENTl) assessed
the TM 11 segment containing the GxxxG m otif using SCAM (substituted cysteine
accessibility method) (67). While all substitutions made to residues within and around the
m otif did not significantly affect function, mutations of glycine 392 and glycine 396 were
not tolerated.

The lack o f adenosine uptake and immunoblots o f surface biotinylated

membrane fractions with no visible signal confirmed that these mutants had severely
reduced protein expression. Though the authors were unsure as to whether the GxxxG
motif of TM 11 was interacting with another helices in the same PfENTl or critical for
homo- or heterodimerization, it is clear that the GxxxG m otif is critical for expression o f
the protein (67). The GxxxG m otif o f TM 11 is highly conserved across the ENT1 family
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and glycine 392 and 396 o f PfENTl are equivalent to glycine 441 and 445 in hENTl
(Figure 2.4). Similar to this study, the mutation o f glycine 445 was not tolerated.
Residues in and around the GxxxG region of TM 11 o f nucleoside transporters are
very sensitive to substitutions. Mutation of the leucine 442 residue of hEN Tl, located in
the middle o f the GxxxG m otif of TM 11, was found to alter both the sensitivity of the
transporter to the inhibitor Dipyridamole, as well as permeant selectivity (88). The
equivalent residue in the Caenorhabditis elegans nucleoside transporter (CeENTl),
isoleucine 429, was found to do the same (88). Mutation o f residue 394 of PfENTl, which
is a polymorphism that is either phenylalanine or leucine, affected the Km of both
adenosine and hypoxanthine transport (67). This residue is within the GxxxG motif of the
transporter and the equivalent residue in hENTl is alanine 443. Other residues adjacent to
the GxxxG region were shown to line the permeation pathway of PfENTl using SCAM
(67). As mentioned previously, mutation of glycine residues within the same GxxxG
region of the PfENTl affected protein expression (67). Another study that made Cterminal truncated variants of hENTl, i.e. in the TM 11 region, observed a loss of
targeting to the plasma membrane to varying degrees with correlating reduction in [3H]
uridine uptake (55).
So based on the literature currently available, residues within and near the GxxxG
m otif o f TM 11 either affected substrate transport and are implicated in the translocation
pathway, or affect protein folding or plasma membrane targeting o f the transporter. The
functional data presented suggests that G445 is important for protein expression of
hENTl. Residue G 163 may play a combined role in either protein expression and/or
functionality.
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The fact that PK15-hENTl-G445L was not expressed and PK15-hENTl-G163L
was only slightly more tolerated, points to the extreme importance o f making the right
amino acid substitution. Glycine residues provide the optimal interface necessary for
other residues to interact thanks to their small, flexible hydrogen side chain (46).
Substituting a glycine with a bulky, hydrophobic P-branched leucine residue is a drastic
change. Based on the constraints of surrounding residues, the glycine to leucine mutation
could potentially introduce steric clash that would result in a non-viable misfolded
protein. Leucine was chosen as an initial assessment o f the GxxxG regions’ potential
contributions to hENTl oligomerization. This decision was made based on a study that
detailed the effects o f various mutations to the GxxxG motif sequence on GpA
dimerization. It was found that substitutions to the glycine residues, particularly the
second glycine residue to a leucine, provided consistently lead to dramatic destabilization
(46).
The next step in the assessment of hENTl GxxxG motifs is to mutate the residues
glycine 163 and glycine 445 to alanines instead. An alanine, with a methyl side chain, is a
more compatible replacement and therefore more likely to maintain the functionality of
the transporter. A study o f the GxxxG m otif in the ATP-binding cassette transporter
subfamily G member 2 (ABCG2) employed site-directed mutagenesis to mutate each of
the glycine residues to both a leucine and an alanine (63). The leucine mutants had lower
levels of protein on immunoblots and extremely impaired substrate transport. The two
alanine mutants, however, had normal protein expression levels and were fully functional.
The authors suggested that the alanine substitution was most likely more tolerated because
there exist AxxxA motifs that enhance thermodynamic protein stabilization (63). The lack
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of functionally capable mutant PK15-hENTl-G163L transporters at the plasma membrane
as well as the lack of PK15-hENTl-G445L protein confirms the harshness o f the leucine
mutation. This reiterates the notion that the effects o f a milder substitution should be
studied.

5.2.3 Blue Native Electrophoresis of the GxxxG mutant: PK15-hENTl-G163L
Since the introduction of a leucine in the place o f G445 interferes with the normal
production of transporter protein, the mutant PK15-hENTl-G445L was not used for BNE
studies. Samples o f PK15-hENTl-G163L membranes, along with wild-type hENTl and
PK-15 NTD membranes as a positive and negative control, respectively, were prepared
and processed as previously described for BNE. The native molecular weight of PK15hENTl-G163L is not different from wild-type hENTl. This suggests that the interaction
that associates hENTl with the observed higher molecular weight complex is not directly
mediated by the G163 residue o f the GxxxG m otif in TM 4 o f the transporter. As
previously discussed, PK15-hENTl-G163L may or may not be present at the plasma
membrane. If the PK15-hENTl-G163L mutant is stuck in the ER or the Golgi, then in
terms o f the native electrophoresis results, the mutation is affecting the targeting of the
final protein complex but not the oligomeric assembly that takes place in the ER. So the
native molecular weight observed is not different between wild-type and the mutant. If the
protein folding and targeting processes are both unaffected by the mutation and PK15hENTl-G163L is present at the plasma membrane, then with respect to the observed
native molecular weight, wild-type hENTl and PK15-hENTl-G163L are not different
because the residue is not affecting the inter- and/ or intra-helical association of the

140
transporter. Instead, the residue is critical to the substrate-binding site and mutation results
in a loss of substrate transport.

5.2.4 Sodium Carbonate Isolation and Blue Native Electrophoresis
Sodium carbonate isolation is a technique that is commonly used to strip
associated proteins based on alkalinity (52). The native complex that wild-type hENTl is
associated with under the nonreducing conditions o f BNE is not disrupted by treatment
with sodium carbonate. There is also no change in the molecular mass of PK15-hENTlG163L. These results suggest that not only is the native ENT1 protein interaction
observed with BNE not disrupted by pH, but that the residue G163 does not contribute to
this interaction. The study conducted by Vickers et al. (86) that observed dimers and
trimers on immunoblots o f hENTl recombinantly expressed in yeast cells chose to follow
up the finding with additional experiments of protein separation under reducing and
nonreducing conditions. No change in staining pattern was observed between the two
conditions, suggesting that disulphide bonds were not responsible for the higher
molecular mass proteins observed (86). At this point, it is not clear whether the higher
molecular mass complex involving ENT1 is due to an oligomer or another protein protein
interaction. Rather, the only conclusive statement that can be made is that this higher
160kDa protein complex is not disrupted by sodium carbonate isolation and that the
residue G163 does not appear to contribute to this higher order size.
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5.3 Conclusion

5.3.1 TM Domains 1 and 2 of hENTl
The findings presented in this thesis support the notion that residues of TM
domains 1 and 2 identified, thus far, generally make minor contributions to the
functionality o f the ENT transporter. The mutants PK15-hENTl-N81A, PK15-hENTlT96A and PK15-hENTl-C87S are functional, indicating that these residues are not crucial
for hENTl protein expression and function. Mutation o f the residue N81 results in slightly
reduced sensitivities to the ENT1 inhibitors NBMPR, draflazine and dilazep. Consistent
with other residues in the TM 2 region, this residue is involved in some manner with the
inhibitor-binding site o f the transporter. The residue T96 appears to have an effect on the
substrate transport capacity o f the hENTl. T96 may not necessarily line the substrate
translocation pathway but may interact indirectly, along with other residues in TM 2, on
the purine-selective component of transport. Protein expression o f the PK15-hENTlG22A mutant was lost during the characterization process and further wbrk is needed to
detail this residue’s importance to hENTl. Initial studies suggest that G22 interacts with
NBMPR binding to the transporter, but does not play a role in substrate uptake. Glycine
residues in nucleoside transporters previously targeted by site-directed mutagenesis are
sensitive to change and have shown poor protein expression (76, 77, 67). Coupled with
the neighbouring PWN m otif that affects hENTl targeting to the plasma membrane, this
could explain the loss o f protein expression with the PK15-hENTl-G22A mutant. On the
other hand, mutation of C87 does not affect the inhibitor binding or substrate transport
capacity o f hENT 1.
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These findings emphasize the fact that no one particular region of the transporter
is solely responsible for optimal inhibitor binding, substrate uptake or protein expression.
This study focused on four residues within the first two TM domains of hENTl.
Mutations to these residues produced minor changes in the affinities o f inhibitor binding
and substrate uptake that mimic previously identified neighbouring residues. This
suggests the combined efforts o f multiple residues working together to modulate the
interaction o f inhibitors and substrate with hENTl. Functionality is a result of the strong
interplay o f transmembrane domains, and no one particular amino acid residue is entirely
responsible.

5.3.2 Oligomerization of hENTl
This thesis also presents the novel finding that hENTl exists as part o f a higher
molecular mass complex when assessed with BNE. To our knowledge, this is the first
intentional investigation of ENT oligomerization. A few studies have observed higher
molecular mass ENT1 species with SDS-PAGE along with the expected ËNT1 monomer
(42, 19, 86, 53). However, there is currently no published literature on the subject of
nucleoside transporter oligomerization. Instead o f a 55 kDa monomer, under the native
conditions o f BNE wild-type hENTl is observed as part o f a 147-180 kDa higher
molecular mass complex. The contributions of two GxxxG motifs in TM domains 4 and
11 o f hENTl to this higher order molecular mass were determined. The mutation of G 163
and G445 residues to leucines were not well tolerated. The mutant PK15-hENTl-G445L
transporter protein is not expressed and was therefore not used for BNE studies. Most
likely the drastic substitution of a glycine with a leucine amino acid introduced steric
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clash that interfered with protein folding. PK15-hENTl-G163L protein is expressed and
the mutation appears to alter NBMPR binding to the transporter. However, the mutant is
incapable o f substrate uptake.
The native molecular mass of the PK15-hENTl-G163L mutant assessed by BNE
was not different from that o f wild-type hENTl. Clearly these glycine residues are
critical to the stability o f the transporter because mutations are not well tolerated. This
stability, however, could either be necessary for the helical associations of domains
within the transporter itself or association with a higher order oligomer complex. The
findings presented here would suggest that the motifs are responsible for internal
transporter stability and do not contribute to the associations of the higher molecular mass
protein complex observed with BNE. However, considering the harsher leucine mutation
and the fact that only one mutant was assessed with BNE, it should be stressed that this is
only an initial study o f the GxxxG motifs in the transporter. These findings are not a
conclusive end statement to the contribution of the GxxxG regions in TM domains 4 and
11 of hENTl and further studies should be performed to do so.

5.4 Future Directions
BNE was used as an initial technique for determining the molecular size of hENTl
in a ‘native’ state, based on its reasonably relative ease o f reproducibility and cost (64).
The capacity of hENTl to run as a higher order oligomer using BNE should most
certainly be validated by other experimental procedures for determining protein-protein
interactions. The results presented in this thesis indicate the presence o f a higher
molecular mass species that cannot be separated to its individual components by sodium
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carbonate isolation. However, they do not detail the specific composition. The next step is
to determine whether the interaction seen is a result of ENT1 homooligomerization,
heteroligomerization amongst other ENT subtypes, or an interaction with other proteins
entirely. To further these initial findings, a number of studies can be performed. In vitro
protein binding and subsequent identification by mass spectrometry (MS) can be used to
determine proteins interacting with hENTl. The only drawback to this technique is that it
requires a large amount o f purified recombinant protein. Once a basic knowledge of
potential partners is gained, techniques like co-immunoprecipitation (Co-IP) and
Fluorescence/Bioluminescence Resonance Energy Transfer (F/BRET) can be used to
monitor protein-protein interactions, including homo- or hetero-oligomerization of ENT
species (51).
In terms o f the GxxxG mutants, as previously discussed, the next step towards
understanding the role of the GxxxG m otif in ENT1 oligomerization is to mutate the
glycine residues, G163 and G445, to alanine, rather than leucine residues. Inducing a
more subtle structural change with alanine substitutions may result in a more functionally
stable transporter that can then be analyzed for its contributions to oligomerization. Again,
the motifs may potentially be interacting with a dimer interface, but could also be
interacting with another TM segment within the same transporter. Other residues
surrounding and within the GxxxG regions should also be assessed. The glycines provide
a structurally flat surface that allows the necessary contacts of larger surrounding amino
acids (70). Perhaps mutations to the glycines disrupt critical folding processes of the
transporter. Additional neighbouring residues should also be targeted to assess the motif
contribution to hENTl oligomerization. It would also be interesting to screen the ENT
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sequence for any other possible known oligomerzation motifs that may play a contributing
role in the state o f ENT 1, as well as to cross check the presence of such motifs in other
ENT subtypes and across other species. Because this project was undertaken in a
recombinant model, it is worthwhile to note that protein interactions seen may be an
artifact of overexpression, and not necessarily relevant to physiological ENT1. As a
continuation to the current work, at some point, these studies should be confirmed in an
endogenous model.
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